<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment for familial amyloid polyneuropathy - Magrinelli, F - 2020 | Cochrane Library</title> <meta content="Pharmacological treatment for familial amyloid polyneuropathy - Magrinelli, F - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012395.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment for familial amyloid polyneuropathy - Magrinelli, F - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012395.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012395.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment for familial amyloid polyneuropathy" name="citation_title"/> <meta content="Francesca Magrinelli" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="francesca.magrinelli@univr.it" name="citation_author_email"/> <meta content="Gian Maria Fabrizi" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Lucio Santoro" name="citation_author"/> <meta content="University Federico II of Naples" name="citation_author_institution"/> <meta content="Fiore Manganelli" name="citation_author"/> <meta content="University Federico II of Naples" name="citation_author_institution"/> <meta content="Giampietro Zanette" name="citation_author"/> <meta content="Pederzoli Hospital" name="citation_author_institution"/> <meta content="Tiziana Cavallaro" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Stefano Tamburin" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012395.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/04/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012395.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012395.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012395.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amyloid Neuropathies, Familial [*drug therapy, mortality]; Benzoxazoles [adverse effects, therapeutic use]; Diflunisal [adverse effects, therapeutic use]; Disease Progression; Oligonucleotides [adverse effects, therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Quality of Life; RNA, Small Interfering [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012395.pub2&amp;doi=10.1002/14651858.CD012395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012395\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012395\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa","zh_HANS","ru","ko","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012395.pub2",title:"Pharmacological treatment for familial amyloid polyneuropathy",firstPublishedDate:"Apr 20, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012395.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012395.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012395.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012395.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012395.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012395.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012395.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012395.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012395.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012395.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2855 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012395.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0118"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-sec-0107"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/appendices#CD012395-sec-0123"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/table_n/CD012395StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/table_n/CD012395StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment for familial amyloid polyneuropathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Francesca Magrinelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0003">Gian Maria Fabrizi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0004">Lucio Santoro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0005">Fiore Manganelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0006">Giampietro Zanette</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0007">Tiziana Cavallaro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information#CD012395-cr-0008">Stefano Tamburin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information/en#CD012395-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 April 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012395.pub2">https://doi.org/10.1002/14651858.CD012395.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012395-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012395-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012395-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012395-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012395-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012395-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012395-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012395-abs-0001" lang="en"> <section id="CD012395-sec-0001"> <h3 class="title" id="CD012395-sec-0001">Background</h3> <p>Disease‐modifying pharmacological agents for transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease‐modifying pharmacological treatment for TTR‐related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors. </p> </section> <section id="CD012395-sec-0002"> <h3 class="title" id="CD012395-sec-0002">Objectives</h3> <p>To assess and compare the efficacy, acceptability, and tolerability of disease‐modifying pharmacological agents for familial amyloid polyneuropathies (FAPs). </p> </section> <section id="CD012395-sec-0003"> <h3 class="title" id="CD012395-sec-0003">Search methods</h3> <p>On 18 November 2019, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We reviewed reference lists of articles and textbooks on peripheral neuropathies. We also contacted experts in the field. We searched clinical trials registries and manufacturers' websites. </p> </section> <section id="CD012395-sec-0004"> <h3 class="title" id="CD012395-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials (RCTs) or quasi‐RCTs investigating any disease‐modifying pharmacological agent in adults with FAPs. </p> <p>Disability due to FAP progression was the primary outcome. Secondary outcomes were severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events during the trial. </p> </section> <section id="CD012395-sec-0005"> <h3 class="title" id="CD012395-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology.</p> </section> <section id="CD012395-sec-0006"> <h3 class="title" id="CD012395-sec-0006">Main results</h3> <p>The review included four RCTs involving 655 people with TTR‐FAP. The manufacturers of the drugs under investigation funded three of the studies. The trials investigated different drugs versus placebo and we did not conduct a meta‐analysis. </p> <p>One RCT compared tafamidis with placebo in early‐stage TTR‐FAP (128 randomised participants). The trial did not explore our predetermined disability outcome measures. After 18 months, tafamidis might reduce progression of peripheral neuropathy slightly more than placebo (Neuropathy Impairment Score (NIS) in the lower limbs; mean difference (MD) ‐3.21 points, 95% confidential interval (CI) ‐5.63 to ‐0.79; P = 0.009; low‐certainty evidence). However, tafamidis might lead to little or no difference in the change of quality of life between groups (Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QOL‐DN) total score; MD ‐4.50 points, 95% CI ‐11.27 to 2.27; P = 0.19; very low‐certainty evidence). No clear between‐group difference was found in the numbers of participants who died (risk ratio (RR) 0.65, 95% CI 0.11 to 3.74; P = 0.63; very low‐certainty evidence), who dropped out due to adverse events (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very low‐certainty evidence), or who experienced at least one severe adverse event during the trial (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very low‐certainty evidence). </p> <p>One RCT compared diflunisal with placebo (130 randomised participants). At month 24, diflunisal might reduce progression of disability (Kumamoto Score; MD ‐4.90 points, 95% CI ‐7.89 to ‐1.91; P = 0.002; low‐certainty evidence) and peripheral neuropathy (NIS plus 7 nerve tests; MD ‐18.10 points, 95% CI ‐26.03 to ‐10.17; P &lt; 0.001; low‐certainty evidence) more than placebo. After 24 months, changes from baseline in the quality of life measured by the 36‐Item Short‐Form Health Survey score showed no clear difference between groups for the physical component (MD 6.10 points, 95% CI 2.56 to 9.64; P = 0.001; very low‐certainty evidence) and the mental component (MD 4.40 points, 95% CI ‐0.19 to 8.99; P = 0.063; very low‐certainty evidence). There was no clear between‐group difference in the number of people who died (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very low‐certainty evidence), in the number of dropouts due to adverse events (RR 2.06, 95% CI 0.39 to 10.87; P = 0.39; very low‐certainty evidence), and in the number of people who experienced at least one severe adverse event (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very low‐certainty evidence) during the trial. </p> <p>One RCT compared patisiran with placebo (225 randomised participants). After 18 months, patisiran reduced both progression of disability (Rasch‐built Overall Disability Scale; least‐squares MD 8.90 points, 95% CI 7.00 to 10.80; P &lt; 0.001; moderate‐certainty evidence) and peripheral neuropathy (modified NIS plus 7 nerve tests ‐ Alnylam version; least‐squares MD ‐33.99 points, 95% CI ‐39.86 to ‐28.13; P &lt; 0.001; moderate‐certainty evidence) more than placebo. At month 18, the change in quality of life between groups favoured patisiran (Norfolk QOL‐DN total score; least‐squares MD ‐21.10 points, 95% CI ‐27.20 to ‐15.00; P &lt; 0.001; low‐certainty evidence). There was little or no between‐group difference in the number of participants who died (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; low‐certainty evidence), dropped out due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; low‐certainty evidence), or experienced at least one severe adverse event (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; low‐certainty evidence) during the trial. </p> <p>One RCT compared inotersen with placebo (172 randomised participants). The trial did not explore our predetermined disability outcome measures. From baseline to week 66, inotersen reduced progression of peripheral neuropathy more than placebo (modified NIS plus 7 nerve tests ‐ Ionis version; MD ‐19.73 points, 95% CI ‐26.50 to ‐12.96; P &lt; 0.001; moderate‐certainty evidence). At week 65, the change in quality of life between groups favoured inotersen (Norfolk QOL‐DN total score; MD ‐10.85 points, 95% CI ‐17.25 to ‐4.45; P &lt; 0.001; low‐certainty evidence). Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low‐certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low‐certainty evidence) compared to placebo. More dropouts due to adverse events were observed in the inotersen than in the placebo group (RR 8.57, 95% CI 1.16 to 63.07; P = 0.035; low‐certainty evidence). </p> <p>There were no studies addressing apolipoprotein AI‐FAP, gelsolin‐FAP, and beta‐2‐microglobulin‐FAP.</p> </section> <section id="CD012395-sec-0007"> <h3 class="title" id="CD012395-sec-0007">Authors' conclusions</h3> <p>Evidence on the pharmacological treatment of FAPs from RCTs is limited to TTR‐FAP. No studies directly compare disease‐modifying pharmacological treatments for TTR‐FAP. Results from placebo‐controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR‐FAP, but further investigations are needed. Since direct comparative studies for TTR‐FAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, long‐term non‐randomised open‐label studies monitoring their efficacy and safety are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012395-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012395-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012395-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012395-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012395-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012395-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012395-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012395-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012395-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012395-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012395-abs-0002" lang="en"> <h3>Drug treatment for familial amyloid polyneuropathy</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this review was to assess whether drugs to treat familial amyloid polyneuropathies (FAPs) reduce disability due to nerve damage, reduce the severity of nerve damage, and improve nutritional status, quality of life, and depression. We also reviewed evidence on side effects. </p> <p><b>Key messages</b> </p> <p>Studies of drug treatments for people with FAP are so far limited to transthyretin‐FAP (also called TTR‐FAP). Four trials have compared a drug with a placebo (an inactive, dummy compound), but none have directly compared drugs with each other. The studies provided evidence that all four drugs studied (tafamidis, diflunisal, patisiran, and inotersen) are probably of benefit for people with TTR‐FAP, but it remains possible that their true effects are different from these results. As research comparing drugs with each other is limited by study size required to demonstrate the superiority of one drug and costs, studies monitoring their effects for longer are needed. </p> <p><b>What was studied in the review?</b> </p> <p>FAPs are a group of hereditary progressive conditions in which insoluble protein deposits (fibrils) affect mainly peripheral nerves (nerves outside the brain and spinal cord). Fibrils are deposited because they are made up of genetically abnormal protein that does not fold properly. This process also occurs in many other organs including the heart, kidneys, and eyes, thus these disorders are complex. The type of protein fibril deposited and the exact genetic defect determine the type of FAP. TTR‐FAP is the most common FAP by far. Although liver transplantation was the only treatment, done in highly selected cases, drugs which may affect the disease course have recently become available for people with TTR‐FAP. </p> <p><b>What are the main results of the review?</b> </p> <p>The review authors found four relevant studies, which involved 655 adults with TTR‐FAP.</p> <p>In one study, people with early‐stage TTR‐FAP received tafamidis or placebo for 18 months. Disability was not measured. The evidence suggested that tafamidis may reduce both the proportion of people with progression of peripheral neuropathy and the mean change (worsening) of nerve damage (based on a score of strength and sensation) compared to placebo. It is uncertain whether tafamidis has an effect on quality of life and the number of deaths, dropouts due to harmful effects or any severe side effects. </p> <p>Evidence from a 24‐month study in people with TTR‐FAP suggested that compared to placebo, diflunisal may slightly decrease disability due to FAP progression and lessen worsening of peripheral neuropathy. It is uncertain whether diflunisal has an effect on quality of life and number of deaths, dropouts due to side effects, and people who experience severe side effects. </p> <p>Results from an 18‐month study in people with TTR‐FAP suggested that compared to placebo, patisiran probably decreases disability due to FAP progression, and lessens worsening of peripheral neuropathy. Quality of life may decline slightly less with patisiran than placebo. Patisiran may lead to little or no difference in mortality, dropouts due to side effects or number of people experiencing severe side effects. </p> <p>In the fourth study, people with TTR‐FAP received inotersen or placebo for 66 weeks. Disability was not measured. This study indicated that inotersen probably reduces worsening of peripheral neuropathy, but may have little effect on the change in quality of life compared to placebo. Inotersen may be associated with numbers of adverse events above the placebo rate, illustrated by an increase in the number of dropouts due to side effects compared to placebo. There was little or no difference in mortality or number of people experiencing severe side effects. </p> <p>The review authors did not find any study addressing drug therapy for people with other types of FAP. </p> <p>Three of the four studies were funded by the manufacturer of the drug investigated.</p> <p><b>How up‐to‐date is this review?</b> </p> <p>The evidence is current to November 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012395-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012395-sec-0118"></div> <h3 class="title" id="CD012395-sec-0119">Implications for practice</h3> <section id="CD012395-sec-0119"> <p>To date, evidence on the pharmacological treatment of familial amyloid polyneuropathies (FAPs) from randomised clinical trials (RCTs) is limited to transthyretin (TTR)‐FAP, and no RCT directly compares disease‐modifying pharmacological treatments for TTR‐FAP. The four RCTs included in this review investigate disease‐modifying drugs for TTR‐FAP versus placebo and are individually either too small, short, or both, for the review authors to draw confident, high‐certainty conclusions about the efficacy, acceptability, and tolerability of the pharmacological agents under investigation, especially in the long term. The review authors underline that the severity of the disease, challenges of new drug development and RCT management, and lack of alternative treatments, necessitate flexibility in clinical practice. Results indicate that patisiran and inotersen are probably beneficial in TTR‐FAP, and tafamidis and diflunisal may be beneficial in TTR‐FAP. The lower certainty of evidence for tafamidis and diflunisal is mainly due to the high dropout rate in their pivotal RCTs. As for safety data, the occurrence of severe adverse events, including glomerulonephritis and thrombocytopenic intracranial haemorrhage with inotersen highlights the need for a close monitoring of renal profile and platelet count in people on this medication. A full assessment of people with TTR‐FAP, including cardiological and ophthalmological assessment is recommended. As direct comparative studies for TTR‐FAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, long‐term non‐randomised open‐label studies to monitor the efficacy and safety of these drugs are needed. </p> </section> <h3 class="title" id="CD012395-sec-0120">Implications for research</h3> <section id="CD012395-sec-0120"> <p>Various approaches have been taken in the research and development of disease‐modifying treatments for TTR‐FAP over the past decades, and a number of pharmacological agents are currently available. Drug development for TTR‐FAP has encountered a number of challenges typically associated with rare genetic conditions, as well as others specific for this complex multisystem disease. </p> <p>First, the number of people available to participate in clinical trials is limited. The pivotal trials enrolled a small number of participants and often showed a high dropout rate. For example, the trial investigating tafamidis presented a higher than anticipated liver transplantation dropout rate, which reduces certainty in the findings (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>). </p> <p>Second, the small participant populations may be highly heterogeneous, both genotypically and phenotypically. Nuances in clinical manifestations and progression of TTR‐FAP are not completely understood due to the lack of natural history studies, especially in nonendemic areas and for uncommon mutations, such as many non‐Val30Met variants. Moreover, genetic, epigenetic, and environmental factors that may influence phenotypic expression should be clarified. These aspects are critical in determining delayed diagnosis and participant enrolment in clinical trials. Therefore, efforts should be undertaken in order to create observational registries worldwide to improve understanding of the disease. In addition, results from RCTs should be critically analysed within homogeneous participant subgroups, in terms of profile of organ involvement and genotype. </p> <p>Third, the detection of appropriate clinically meaningful outcomes and relevant duration of follow‐up to measure efficacy and safety are mandatory, and require understanding of their rate of occurrence and variability, both of which contribute to difficulties in powering a study. The follow‐up periods of available RCTs were too short for evaluation of long‐term safety and efficacy in relation to the natural progression of the disease. On the other hand, the combination of double‐blind trials and open‐label extension studies resembles the design of a delayed‐start trial, and is aimed at distinguishing between long‐term effects on disease progression and effects on symptoms. The design of these studies (in which only the initial phase is randomised, double‐blind, and placebo‐controlled) precludes direct assessment of the extent to which investigational drugs preserve neurologic function and quality of life in the long term, compared with placebo. However, it may represent a good compromise between the need to promptly provide a possibly beneficial treatment to people with a severe progressive disorder and the challenges of drug development. A consensus on the best surrogate endpoints or biomarkers to consider in clinical trials may help future direct or indirect comparisons between different drugs. </p> <p>Fourth, as TTR‐related amyloidosis is a multisystem disorder, evaluation of treatment efficacy in future clinical trials for FAP should be extended to other involved organs, including the heart and eyes. Available pharmacological treatments for TTR‐FAP are not curative at the moment; at most, they may change severe phenotypes into milder ones. As a chronic and progressive condition, TTR‐FAP requires ongoing treatment and management of complications of long‐standing disease. In particular, monitoring long‐term complications, such as cardiomyopathy, ophthalmic manifestations and leptomeningeal involvement is necessary. The optimal duration of treatment is uncertain and the lack of long‐term data from RCTs hampers considerations of quality of life. </p> <p>Finally, as for other orphan drugs, development of pharmacological treatments for TTR‐FAP may be influenced by potential conflict of interest of patient advocacy organisations, industry sponsorship, and media coverage, which may overemphasise benefits and harms. </p> <p>Future trials should use sensitive and validated disability and clinical scores that are likely to extract meaningful effects and allow direct or indirect comparisons of results. Cost‐effectiveness measurements should also be considered in future trials, as the treatments that have been used and those that are likely to be used in the future are expensive. Trial endpoints should also be planned according to the chronicity of the disorder and meaningful in patient terms, particularly overall disability. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012395-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012395-sec-0008"></div> <div class="table" id="CD012395-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with early‐stage TTR‐FAP<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> tafamidis<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tafamidis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability due to FAP progression was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b> (expressed as the change in NIS‐LL) </p> <p>Scale from: 0 (normal) to 88 (total impairment)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline NIS‐LL score in the placebo group was <b>11.44</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>5.40</b> points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NIS‐LL score in the tafamidis group was <b>3.21</b> points lower (better) than in the placebo group<br/> (<b>5.63</b> points lower to <b>0.79</b> points lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (1 RCT)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID is 2 NIS‐LL points according to a Peripheral Nerve Society consensus group (<a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a>). </p> <p>Tafamidis probably slightly reduces the number of people with progression of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in 35‐Item Norfolk QOL‐DN total score)<br/> Scale from: ‐2 (best possible quality of life) to 138 (worst possible quality of life)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>30.80</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>6.90</b> points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the tafamidis group was <b>4.50</b> points lower (better) than in the placebo group<br/> (<b>11.27</b> points lower to <b>2.27</b> points higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (1 RCT)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID was not provided nor reported in the literature.</p> <p>Quality of life may decline slightly less with tafamidis than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b><br/> (0.11 to 3.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of participants who died during the trial compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b><br/> (1 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.29</b><br/> (0.30 to 5.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of dropouts due to adverse events compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/> (1 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/> (0.37 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of participants experiencing at least one severe adverse event compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b><br/> (3 to 29) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>NIS‐LL:</b> Neuropathy Impairment Score of the lower limbs; <b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Intention‐to‐treat population.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by one level for serious imprecision (CI encompassed a clinically important effect and little or no effect).<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision (CI is wide and includes the possibility of both harms and benefits) and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>Randomised population (safety population).<br/> <sup>f</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by two levels for very serious imprecision (small event numbers; and CI includes the possibility of both harms and benefits) and by one level for serious indirectness (events collected by a non‐systematic assessment). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012395-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> diflunisal<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with diflunisal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> (expressed as the change in Kumamoto Score) </p> <p>Scale from: 0 (normal) to 102 (worst disease severity).<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Kumamoto Score in the placebo group was <b>16.7</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>8.0</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Kumamoto Score in the diflunisal group was <b>4.90</b> points lower (better) than in the placebo group (<b>7.89</b> points lower to <b>1.91</b> points lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Diflunisal probably slightly decreases disability due to FAP progression compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b> (expressed as the change in NIS+7) </p> <p>Scale from: 0 (normal) to 270 (total impairment)<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline NIS+7 score in the placebo group was <b>59.0</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>26.3</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NIS+7 score in the diflunisal group was <b>18.10</b> points lower (better) than in the placebo group (<b>26.03</b> points lower to <b>10.17</b> points lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID detectable by neuromuscular experts is 2 NIS+7 points according to the international Peripheral Nerve Society (<a href="./references#CD012395-bbs2-0055" title="Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Annals of Neurology1995;38(3):478–82. [DOI: 10.1002/ana.410380323; PUBMED: 7668839] ">PNS 1995</a>). </p> <p>Diflunisal probably slightly reduces the worsening of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in SF‐36 physical component score) </p> <p>Scale from: 0 (worst possible quality of life) to 100 (best possible quality of life)<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline SF‐36 QOL score (physical component) in the placebo group was <b>34.8</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>4.9</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SF‐36 QOL score (physical component) in the diflunisal group was <b>6.10</b> points higher (better) than in the placebo group (<b>2.56</b> points higher to <b>9.64</b> points higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID proposed in the <a href="./references#CD012395-bbs2-0065" title="User's manual for the SF‐36v2 survey. 3rd ed. Lincoln (RD), Quality Metric Incorporated2011. ">SF‐36v2 2011</a> is 2 points on the physical component summary. </p> <p>QOL (physical status) may decline slightly less with diflunisal than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in SF‐36 mental component score) </p> <p>Scale from: 0 (worst possible quality of life) to 100 (best possible quality of life).<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline SF‐36 QOL score (mental component) in the placebo group was <b>46.5</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>0.9</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SF‐36 QOL score (mental component) in the diflunisal group was <b>4.40</b> points higher (better) than in the placebo group (<b>0.19</b> points lower to <b>8.99</b> points higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID proposed in the <a href="./references#CD012395-bbs2-0065" title="User's manual for the SF‐36v2 survey. 3rd ed. Lincoln (RD), Quality Metric Incorporated2011. ">SF‐36v2 2011</a> is 3 points on the mental component summary. </p> <p>Quality of life (mental status) may decline slightly less with diflunisal than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b><br/> (0.15 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is evidence that there may be fewer deaths among people treated with diflunisal</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/> (2 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.06</b><br/> (0.39 to 10.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diflunisal may increase the number of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b><br/> (3 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b><br/> (0.18 to 3.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diflunisal may have no clear effect on the number of participants experiencing at least one severe adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (1 to 20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>NIS+7:</b> Neuropathy Impairment Score plus 7 nerves test; <b>QOL</b> : quality of life; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SF‐36:</b> 36‐Item Short‐Form Health Survey; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by one level for serious imprecision.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision and by one level for serious indirectness (data regarding QOL provided for SF‐36 physical and mental components separately).<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision (CI includes the possibility of both harms and benefits) and by one level for serious indirectness (data regarding QOL provided for SF‐36 physical and mental components separately and mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012395-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> patisiran<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with patisiran</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> (expressed as the change in R‐ODS) </p> <p>Scale from: 0 (worst disability) to 48 (normal)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline R‐ODS score in the placebo group was <b>29.8</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>8.9</b> points.<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in R‐ODS score in the patisiran group was <b>8.90</b> points higher (better) than in the placebo group (<b>7.00</b> points higher to <b>10.80</b> points higher).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Patisiran probably decreases disability due to FAP progression compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b><br/> (expressed as the change in mNIS+7ALN) </p> <p>Scale from: 0 (normal) to 304 (total impairment)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline mNIS+7ALN score in the placebo group was <b>74.6</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>27.96</b> points.<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mNIS+7ALN score in the patisiran group was <b>33.99</b> points lower (better) than in the placebo group (<b>39.86</b> points lower to <b>28.13</b> points lower).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not available for this modified NIS+7 scores.</p> <p>Patisiran probably slightly reduces the worsening of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> (expressed as the change in 35‐Item Norfolk QOL‐DN total score) </p> <p>Scale from: ‐4 (best possible quality of life) to 136 (worst possible quality of life)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>55.5</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>14.4</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the patisiran group was <b>21.10</b> points lower (better) than in the placebo group (<b>27.20</b> points lower to <b>15.00</b> points lower).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Quality of life may decline slightly less with patisiran than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b><br/> (0.21 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be no clear difference between the patisiran group and the placebo group in the number of participants who died during the trial. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (2 to 14) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.33</b><br/> (0.13 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between the patisiran group and the placebo group in the number of dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (2 to 12) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.91</b><br/> (0.64 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between the patisiran group and the placebo group in the number of participants with at least one severe adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b><br/> (26 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval;<b>FAP:</b> familial amyloid polyneuropathy;<b>MCID:</b> minimum clinically important difference; <b>mNIS+7ALN:</b> modified Neuropathy Impairment Score plus 7 nerves test (Alnylam);<b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial;<b>ROD‐S:</b> Rasch‐built Overall Disability Scale; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Means change from baseline and mean differences between groups refer to least‐squares means and least‐squares mean differences, respectively.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for serious imprecision.<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for serious imprecision and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits).<br/> <sup>f</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012395-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> inotersen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inotersen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability due to FAP progression was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b><br/> (expressed as the change in mNIS+7Ionis) </p> <p>Scale from: ‐22.3 (normal) to 346.3 (total impairment)</p> <p>Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline mNIS+7Ionis score in the placebo group was <b>74.8</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>23.89</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mNIS+7Ionis score in the inotersen group was <b>19.73</b> points lower (better) than in the placebo group (<b>26.50</b> lower to <b>12.96</b> lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MCID detectable is 2 points.</p> <p>Inostersen probably reduces the worsening of peripheral neuropathy compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in 35‐Item Norfolk QOL‐DN total score) </p> <p>Scale from: ‐4 (best possible quality of life) to 136 (worst possible quality of life)</p> <p>Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>48.7</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>10.77</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the inotersen group was <b>10.85</b> points lower (better) than in the placebo group (<b>17.25</b> lower to <b>4.45</b> lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MICD not provided nor reported in the literature.</p> <p>Inotersen may have little effect on the change in QOL.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.94</b><br/> (0.33 to 105.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of participants who died during the trial may be greater in the inotersen group than in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0/60 deaths</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5/112 deaths</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 8.57</b><br/> (1.16 to 63.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of dropouts due to adverse events may be greater in the inotersen group than the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/> (2 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.48</b><br/> (0.85 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of participants experiencing at least one severe adverse event may be greater in the inotersen group than in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b><br/> (18 to 56) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>mNIS+7Ionis</b> : modified Neuropathy Impairment Score plus 7 nerves test (Ionis version); <b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Mean change from baseline and mean differences between groups refer to least‐squares means and least‐squares mean differences, respectively.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for serious imprecision.<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for serious imprecision and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits).<br/> <sup>f</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012395-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012395-sec-0009"></div> <section id="CD012395-sec-0010"> <h3 class="title" id="CD012395-sec-0010">Description of the condition</h3> <p>Familial amyloid polyneuropathies (FAPs) are a group of relentless, disabling and life‐threatening hereditary polyneuropathies affecting the somatic and autonomic components of the peripheral nervous system. FAPs are due to endoneurial deposition of amyloid, an insoluble substance constituted from misfolded mutated proteins that aggregate in nonbranching fibrils oriented in a β‐pleated sheet structure. Extracellular deposition of amyloid fibrils usually also occurs in many organs, including the heart, kidneys and eyes. Therefore, FAPs fall into the category of multisystem diseases (<a href="./references#CD012395-bbs2-0053" title="Planté‐BordeneuveV , SaidG . Familial amyloid polyneuropathy. Lancet Neurology2011;10(12):1086‐97. ">Planté‐Bordeneuve 2011</a>). According to the precursor proteins involved in amyloidogenesis, FAPs are classified as (<a href="./references#CD012395-bbs2-0044" title="LunnM , HannaM , HowardR , PartonM , RahmanS , ReillyM , et al. Nerve and muscle disease. In: ClarkeC , HowardR , RossorM , ShorvonS editor(s). Neurology: a Queen Square Textbook. 2nd Edition. Oxford, UK: Wiley Blackwell, 2016:391‐473. ">Lunn 2016</a>): </p> <p> <ul id="CD012395-list-0001"> <li> <p>transthyretin (TTR)‐FAP, formerly termed FAP type I (Portuguese–Swedish–Japanese type) and type II (Indiana‐Swiss or Maryland‐German type); </p> </li> <li> <p>apolipoprotein AI (ApoAI)‐FAP, also referred to as FAP type III, Van Allen type or Iowa type; </p> </li> <li> <p>gelsolin (Gel)‐FAP, previously known as FAP type IV, Finnish type or Meretoja type; and </p> </li> <li> <p>beta‐2‐microglobulin (B2M)‐FAP.</p> </li> </ul> </p> <p>Symptoms suggestive of peripheral neuropathy were reported in a single case of hereditary amyloidosis due to a mutation in the gene encoding lysozyme, but electrodiagnostic tests and nerve biopsy were not performed to confirm the diagnosis (<a href="./references#CD012395-bbs2-0051" title="NasrSH , DasariS , MillsJR , TheisJD , ZimmermannMT , FonsecaR , et al. Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype. Journal of the American Society of Nephrology2017;28(2):431‐8. ">Nasr 2017</a>). </p> <p>FAPs have an autosomal dominant pattern of inheritance. Age at onset, symptomatology, pattern of organ involvement and disease progression of these conditions can be highly variable (<a href="./references#CD012395-bbs2-0053" title="Planté‐BordeneuveV , SaidG . Familial amyloid polyneuropathy. Lancet Neurology2011;10(12):1086‐97. ">Planté‐Bordeneuve 2011</a>; <a href="./references#CD012395-bbs2-0067" title="SipeJD , BensonMD , BuxbaumJN , IkedaS , MerliniG , SaraivaMJ , et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid2014;21(4):221‐4. ">Sipe 2014</a>). </p> <section id="CD012395-sec-0011"> <h4 class="title">TTR‐FAP</h4> <p>TTR‐FAP was originally described by Andrade in Portuguese families and then recognised in Sweden, Japan, Ireland, and worldwide (<a href="./references#CD012395-bbs2-0019" title="AndradeC . A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain1952;75(3):408–27. ">Andrade 1952</a>; <a href="./references#CD012395-bbs2-0062" title="RowczenioD , WechalekarA . Mutations in transthyretin gene. amyloidosismutations.com/mut‐attr.php2015. ">Rowczenio 2015</a>). Its overall prevalence is estimated to be 0.87 to 1.1 per one million people (<a href="./references#CD012395-bbs2-0018" title="AdamsA , ThéaudinM , CauquilC , AlgalarrondoV , SlamaM . FAP neuropathy and emerging treatments. Current Neurology and Neuroscience Reports2014;14(3):435‐46. ">Adams 2014</a>). TTR is a plasma protein which is mainly synthesised by the liver and involved in the transport of thyroid hormones and retinol (vitamin A). The clinical spectrum of TTR‐related amyloidosis encompasses FAP, familial amyloid cardiomyopathy, ocular and leptomeningeal amyloidosis, whereas renal involvement is uncommon (<a href="./references#CD012395-bbs2-0058" title="RapezziC , QuartaCC , ObiciL , PerfettoF , LonghiS , SalviF , et al. Disease profile and differential diagnosis of hereditary transthyretin‐related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal2013;34(7):520‐8. ">Rapezzi 2013</a>). To date, more than 120 amyloidogenic mutations in the <i>TTR</i> gene have been described (<a href="./references#CD012395-bbs2-0061" title="RowczenioDM , NoorI , GillmoreJD , LachmannHJ , WhelanC , HawkinsPN , et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation2014;35(9):E2403‐12. [10.1002/humu.22619] ">Rowczenio 2014</a>). Some mutations are associated with particular phenotypes, with prominent neurological or cardiac involvement (<a href="./references#CD012395-bbs2-0057" title="RapezziC , QuartaCC , RivaL , LonghiS , GallelliI , LorenziniM , et al. Transthyretin‐related amyloidoses and the heart: a clinical overview. Nature Reviews. Cardiology2010;7(7):398‐408. ">Rapezzi 2010</a>; <a href="./references#CD012395-bbs2-0058" title="RapezziC , QuartaCC , ObiciL , PerfettoF , LonghiS , SalviF , et al. Disease profile and differential diagnosis of hereditary transthyretin‐related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal2013;34(7):520‐8. ">Rapezzi 2013</a>). However, a single gene mutation does not necessarily account for a single phenotype and a significant intramutation and intrafamilial variability, as well as differences in natural history within and among mutations are reported (<a href="./references#CD012395-bbs2-0045" title="MarianiLL , LozeronP , ThéaudinM , MinchevaZ , SignateA , DucotB , et al. Genotype‐phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Annals of Neurology2015;78(6):901‐16. ">Mariani 2015</a>). In addition to genetic factors, environmental and epigenetic determinants may influence phenotypic expression and/or variability of age at onset (<a href="./references#CD012395-bbs2-0057" title="RapezziC , QuartaCC , RivaL , LonghiS , GallelliI , LorenziniM , et al. Transthyretin‐related amyloidoses and the heart: a clinical overview. Nature Reviews. Cardiology2010;7(7):398‐408. ">Rapezzi 2010</a>; <a href="./references#CD012395-bbs2-0054" title="Planté‐BordeneuveV . Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology2018;265(4):976‐83. ">Planté‐Bordeneuve 2018</a>). The Val30Met substitution is the most frequent mutation causing TTR‐FAP and is present in large foci in Portugal, Japan and Sweden, thus giving rise to the so called “endemic Val30Met TTR‐FAP phenotype”. Cases of Val30Met TTR‐related amyloidosis reported outside the endemic geographic foci are referred to as “nonendemic Val30Met TTR‐FAP phenotypes”. Endemic Val30Met TTR‐FAP typically begins in the fourth decade of life (Portuguese and Japanese cases) or later (Swedish cases), manifesting as a slowly progressive, length‐dependent, sensorimotor polyneuropathy, often associated with autonomic involvement. Clinical manifestations include loss of superficial sensation, such as nociception and thermal sensations, neuropathic pain, orthostatic hypotension, sexual impotence, neurogenic bladder and gastrointestinal dysfunction. Restrictive cardiomyopathy progressing to congestive heart failure, arrhythmias and conduction blocks is a later manifestation. Nonendemic Val30Met TTR‐FAP usually shows higher age at onset (sixth or seventh decade of life), extreme male predominance, broader phenotypic heterogeneity and markedly low age‐related penetrance, so that a positive family history is less frequent and the diagnosis often delayed. Cardiac involvement can be very prominent already at presentation and autonomic dysfunction is typically milder. Age at onset of TTR‐FAP is quite variable, particularly for the Val30Met‐related form in endemic or nonendemic geographic areas, so that early‐onset (&lt; 50 years) and late‐onset (&gt; 50 years) phenotypes have been defined. Phenotypes related to non‐Val30Met mutations vary considerably, encompassing selective and nonselective neurological, cardiac and oculoleptomeningeal involvement (<a href="./references#CD012395-bbs2-0057" title="RapezziC , QuartaCC , RivaL , LonghiS , GallelliI , LorenziniM , et al. Transthyretin‐related amyloidoses and the heart: a clinical overview. Nature Reviews. Cardiology2010;7(7):398‐408. ">Rapezzi 2010</a>). Walking difficulties requiring aid (stage 2) occur after a mean disease duration of six years, with confinement to a wheelchair (stage 3) on average after 10 years of disease (<a href="./references#CD012395-bbs2-0027" title="CoutinhoP , Martins da SilvaA , Lopes LimaJ , Resende BarbosaA . Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: GlennerG , CostaP , deFreitasA editor(s). Amyloid and Amyloidosis. Amsterdam: Execerpta Medica, 1980:88‐98. ">Coutinho 1980</a>; <a href="./references#CD012395-bbs2-0018" title="AdamsA , ThéaudinM , CauquilC , AlgalarrondoV , SlamaM . FAP neuropathy and emerging treatments. Current Neurology and Neuroscience Reports2014;14(3):435‐46. ">Adams 2014</a>). Studies in Portuguese people with TTR‐FAP indicate that death occurs within a mean interval of 10.8 years after the onset of symptoms (<a href="./references#CD012395-bbs2-0037" title="HundE . Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin‐mediated amyloidosis. The Application of Clinical Genetics2012;5:37‐41. ">Hund 2012</a>). </p> </section> <section id="CD012395-sec-0012"> <h4 class="title">ApoAI‐FAP</h4> <p>ApoAI‐FAP was first recognised in Iowa. ApoAI is the major protein constituent of plasma high‐density lipoprotein. ApoAI is synthesised in the liver and small intestine in approximately the same proportions. ApoAI‐FAP usually begins in the fourth decade of life and is characterised by amyloid deposition in major organs, including the liver, gastrointestinal tract and kidneys, leading to severe gastric ulcer disease and renal failure. Although a length‐dependent polyneuropathy with slow progression can occur in ApoAI‐related amyloidosis, it is not a major feature of the disease. Four mutations in the <i>APOAI</i> gene are associated with the neuropathic pattern of ApoAI‐related amyloidosis (Gly26Arg, Leu174Ser, His155Metfs*46, Ala154Glyfs*48) (<a href="./references#CD012395-bbs2-0061" title="RowczenioDM , NoorI , GillmoreJD , LachmannHJ , WhelanC , HawkinsPN , et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation2014;35(9):E2403‐12. [10.1002/humu.22619] ">Rowczenio 2014</a>). </p> </section> <section id="CD012395-sec-0013"> <h4 class="title">Gel‐FAP</h4> <p>Gel‐FAP was first identified in Finland, but sporadic cases are recognised worldwide. Gel is a calcium‐dependent actin‐binding protein. Two point mutations in the <i>GEL</i> gene (Asp187Asn, Asp187Tyr) are known to cause neuropathic forms of Gel‐related amyloidosis (<a href="./references#CD012395-bbs2-0053" title="Planté‐BordeneuveV , SaidG . Familial amyloid polyneuropathy. Lancet Neurology2011;10(12):1086‐97. ">Planté‐Bordeneuve 2011</a>; <a href="./references#CD012395-bbs2-0061" title="RowczenioDM , NoorI , GillmoreJD , LachmannHJ , WhelanC , HawkinsPN , et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation2014;35(9):E2403‐12. [10.1002/humu.22619] ">Rowczenio 2014</a>). The first manifestations of Gel‐amyloidosis occur at age 25 to 30 years and include corneal lattice dystrophy, cranial neuropathies (typically unilateral or bilateral facial paralysis), peripheral sensory neuropathy, and abnormal skin laxity. Cardiac, renal and pharyngeal abnormalities are less common. The clinical course of Gel‐FAP is slow and quite benign, since life‐threatening cardiac and renal complications are rare. </p> </section> <section id="CD012395-sec-0014"> <h4 class="title">B2M‐FAP</h4> <p>A single French family has been reported with an Asp76Asn mutation in the <i>B2M</i> gene causing gastrointestinal involvement (chronic diarrhoea with weight loss, autonomic and sensorimotor neuropathy, and persistent sicca syndrome) (<a href="./references#CD012395-bbs2-0072" title="ValleixS , GillmoreJD , BridouxF , MangionePP , DoganA , NedelecB , et al. Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β2‐Microglobulin. New England Journal of Medicine2012;366(24):2276‐83. ">Valleix 2012</a>; <a href="./references#CD012395-bbs2-0061" title="RowczenioDM , NoorI , GillmoreJD , LachmannHJ , WhelanC , HawkinsPN , et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation2014;35(9):E2403‐12. [10.1002/humu.22619] ">Rowczenio 2014</a>). </p> <p>ApoAI‐FAP and Gel‐FAP are very rare and cases of B2M‐FAP are anecdotal, so the worldwide prevalence of these conditions is unknown. </p> <p>The diagnosis of FAP is often challenging because of phenotypic and genotypic heterogeneity, especially in the absence of family history and when the clinical presentation is atypical. Amyloidosis is diagnosed by demonstration of amyloid in tissue biopsy specimens, where it appears as Congo red–binding material with characteristic apple‐green birefringence under cross‐polarised light. DNA testing to identify an amyloidogenic gene mutation is necessary to confirm the diagnosis of FAP (<a href="./references#CD012395-bbs2-0053" title="Planté‐BordeneuveV , SaidG . Familial amyloid polyneuropathy. Lancet Neurology2011;10(12):1086‐97. ">Planté‐Bordeneuve 2011</a>). In recent years, a number of diagnostic tools have been investigated in people with TTR‐FAP. These include magnetic resonance neurography (<a href="./references#CD012395-bbs2-0039" title="KollmerJ , HundE , HornungB , HegenbartU , SchönlandSO , KimmichC , et al. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain2015;138(Pt 3):549‐62. ">Kollmer 2015</a>; <a href="./references#CD012395-bbs2-0040" title="KollmerJ , SahmF , HegenbartU , PurruckerJC , KimmichC , SchönlandSO , et al. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology2017;89(5):475‐84. ">Kollmer 2017</a>), skin biopsy for the evaluation of intraepidermal nerve fiber density (<a href="./references#CD012395-bbs2-0046" title="MasudaT , UedaM , SuenagaG , MisumiY , TasakiM , IzakiA , et al. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy. Neurology2017;88(23):2192‐7. ">Masuda 2017</a>), and Sudoscan technology for the measurement of electrochemical skin conductance (<a href="./references#CD012395-bbs2-0024" title="CastroJ , MirandaB , CastroI , deCarvalhoM , ConceiçãoI . The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clinical Neurophysiology2016;127(5):2222‐7. ">Castro 2016</a>). Timely detection of clinical manifestations of TTR‐FAP and prompt definitive diagnosis are critical for appropriate treatment and optimal outcomes. Asymptomatic gene carriers should be monitored regularly for early recognition of symptoms and signs. The new diagnostic tools look set to permit an earlier and more reliable diagnosis of this condition (<a href="./references#CD012395-bbs2-0054" title="Planté‐BordeneuveV . Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology2018;265(4):976‐83. ">Planté‐Bordeneuve 2018</a>). </p> </section> </section> <section id="CD012395-sec-0015"> <h3 class="title" id="CD012395-sec-0015">Description of the intervention</h3> <p>The treatment of FAPs requires a multidisciplinary approach, including:</p> <p> <ul id="CD012395-list-0002"> <li> <p>disease‐modifying treatments for stopping or slowing down the progression of amyloidogenesis;</p> </li> <li> <p>pharmacological agents to manage the symptoms of peripheral and autonomic neuropathy (e.g. neuropathic pain, orthostatic hypotension, bladder and gastrointestinal disturbances); and </p> </li> <li> <p>treatment of complications due to severe organ involvement by amyloidosis (i.e. effects on the heart, eye, or kidney). </p> </li> </ul> </p> <p>Overall, <i>TTR</i> gene mutations account for the majority of FAP cases (<a href="./references#CD012395-bbs2-0061" title="RowczenioDM , NoorI , GillmoreJD , LachmannHJ , WhelanC , HawkinsPN , et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation2014;35(9):E2403‐12. [10.1002/humu.22619] ">Rowczenio 2014</a>), and clinical trials have focused on TTR‐FAP to date. </p> <p>Liver transplantation was the only treatment option in TTR‐FAP in the pre‐pharmacological era. Since TTR is synthesised mainly in the liver, liver transplantation suppresses the main source of mutant TTR. Liver transplantation surgery has shown a favourable effect on the progression of peripheral neuropathy in Val30Met TTR‐FAP even in the long term. However, autonomic dysfunction is unchanged after liver transplantation, and cardiac, renal, and oculoleptomeningeal manifestations of the disease are influenced to a lesser degree, if at all. Indeed, long‐term disease‐related complications of liver transplantation include TTR‐related cerebral amyloid angiopathy and cardiomyopathy (<a href="./references#CD012395-bbs2-0054" title="Planté‐BordeneuveV . Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology2018;265(4):976‐83. ">Planté‐Bordeneuve 2018</a>), as well as resultant TTR‐FAP in recipients of explanted FAP liver after a “domino” procedure. People with TTR‐FAP and severe renal or heart failure may benefit from a combined kidney‐liver or heart‐liver transplant (<a href="./references#CD012395-bbs2-0017" title="AdamsD . Recent advances in the treatment of familial amyloid polyneuropathy. Therapeutic Advances in Neurological Disorders2013;6(2):129‐39. ">Adams 2013</a>). However, large numbers of people with TTR‐FAP are not suitable transplant candidates, and the development of pharmacological disease‐modifying options has been an active field of research over the last decades, with a number of completed and ongoing trials (<a href="./references#CD012395-bbs2-0030" title="DubreyS , AckermannE , GillmoreJ . The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal2015;91(1078):439‐48. ">Dubrey 2015</a>). Our review focused on disease‐modifying pharmacological agents for FAP, which are expected to be the only treatment options for the majority of the FAP population. We did not consider symptomatic agents for neuropathic pain, orthostatic hypotension, or bladder and gastrointestinal disturbances, as these are covered in other reviews (<a href="./references#CD012395-bbs2-0047" title="MauleS , PapottiG , NasoD , MagninoC , TestaE , VeglioF . Orthostatic hypotension: evaluation and treatment. Cardiovascular &amp; Hematological Disorders Drug Targets2007;7(1):63‐70. ">Maule 2007</a>; <a href="./references#CD012395-bbs2-0038" title="KemplerP , AmarencoG , FreemanR , FrontoniS , HorowitzM , StevensM , et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes/Metabolism Research and Reviews2011;27(7):665‐77. ">Kempler 2011</a>; <a href="./references#CD012395-bbs2-0025" title="ChiangMC , TsengMT , PanCL , ChaoCC , HsiehST . Progress in the treatment of small fiber peripheral neuropathy. Expert Review of Neurotherapeutics2015;15(3):305‐13. ">Chiang 2015</a>), nor did we discuss treatments for complications of severe organ involvement. </p> </section> <section id="CD012395-sec-0016"> <h3 class="title" id="CD012395-sec-0016">How the intervention might work</h3> <p>Pharmacologic disease‐modifying strategies for TTR‐FAP (some of which are approved and some are still under investigation) may involve a number of classes of drugs: </p> <p> <ul id="CD012395-list-0003"> <li> <p>amyloid kinetic stabilisers, such as tafamidis and diflunisal, which bind mutant misfolded TTR, preventing its aggregation in amyloid fibrils; </p> </li> <li> <p>amyloid matrix solvents, such as doxycycline and taurodeoxycholic acid, which act to disrupt deposited amyloid fibrils; and </p> </li> <li> <p>amyloid precursor inhibitors (i.e. gene therapy with antisense oligonucleotides and small interfering RNA ), which block expression of both mutant and wild type TTR reducing amyloid precursor protein synthesis. </p> </li> </ul> </p> <p>In future, people with TTR‐FAP might benefit from immunisation against amyloid precursors (<a href="./references#CD012395-bbs2-0030" title="DubreyS , AckermannE , GillmoreJ . The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal2015;91(1078):439‐48. ">Dubrey 2015</a>). A number of antibodies, including monoclonal antibodies against TTR and antibodies against serum amyloid P, are undergoing testing in people with various forms of amyloidosis (<a href="./references#CD012395-bbs2-0054" title="Planté‐BordeneuveV . Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology2018;265(4):976‐83. ">Planté‐Bordeneuve 2018</a>). </p> <p>No specific disease‐modifying agent for ApoAI‐FAP, Gel‐FAP, and B2M‐FAP is currently available. </p> </section> <section id="CD012395-sec-0017"> <h3 class="title" id="CD012395-sec-0017">Why it is important to do this review</h3> <p>The purpose of this review was firstly to evaluate the current level of evidence for pharmacologic disease‐modifying treatments for FAPs, secondly to compare the efficacy of different disease‐modifying treatments for FAPs, and thirdly to highlight gaps in knowledge that require further investigation. The review is intended for people with FAPs, healthcare professionals, and researchers. We hope that it will draw attention to, and be a stimulus for, more research in this area. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012395-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012395-sec-0018"></div> <p>To assess and compare the efficacy, acceptability, and tolerability of disease‐modifying pharmacological agents for familial amyloid polyneuropathies (FAPs). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012395-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012395-sec-0019"></div> <section id="CD012395-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012395-sec-0021"> <h4 class="title">Types of studies</h4> <p>As recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012395-bbs2-0036" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), we included all identified randomised clinical trials (RCTs) or quasi‐RCTs of pharmacological disease‐modifying agents for familial amyloid polyneuropathies (FAPs), compared to placebo or to other disease‐modifying agents. Quasi‐RCTs are studies in which participants are allocated to groups using a method that is partially systematic (e.g. by alternation, case record number, or date of birth). We reported evidence for pharmacological agents only investigated in non‐randomised studies, such as cohort studies, case‐control studies or case reports, in the <a href="#CD012395-sec-0107">Discussion</a> section. We included studies reported as full‐text, those published as abstract only, and unpublished data. We did not impose any restrictions as to language of publication. </p> </section> <section id="CD012395-sec-0022"> <h4 class="title">Types of participants</h4> <p>We included studies of people aged 18 years or older, of either gender, with a diagnosis of FAP based on clinical or neurophysiological evidence of polyneuropathy, or both, and positive DNA testing for <i>TTR</i> , <i>APOAI</i> , <i>GEL</i> , or <i>B2M</i> gene mutations, irrespective of biopsy confirmation of amyloid deposits. We included people with FAP as the leading cause of their neuropathy. We excluded people whose neuropathy was attributable to another cause but not those who had comorbidities that may be associated with a neuropathy, where the presenting neuropathy was FAP‐related. </p> </section> <section id="CD012395-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We considered any disease‐modifying pharmacological intervention for FAP in any dose and by any route, compared to placebo, no intervention, or any other active comparator. We allowed any previous or concomitant treatment except other FAP disease‐modifying agents. </p> </section> <section id="CD012395-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>As with many rare diseases, there were no validated outcome measures specific for FAP in the era preceding the first clinical trials in this area. Therefore, measures of disease progression and nerve impairment with demonstrated sensitivity and specificity in other axonal neuropathies (e.g. Charcot‐Marie Tooth disease (CMT) or diabetic polyneuropathy) were included. The tools used to assess the progression of transthyretin (TTR)‐FAP have been refined after the first trials on TTR stabilisers. The Neuropathy Impairment Score (NIS) (<a href="./references#CD012395-bbs2-0031" title="DyckPJ , LitchyWJ , LehmanKA , HokansonJL , LowPA , O'BrienPC . Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology1995;45(6):1115‐21. ">Dyck 1995</a>), the NIS of the lower limbs (NIS‐LL) (<a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a>; <a href="./references#CD012395-bbs2-0021" title="BrilV . NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology1999;41(Suppl 1):8‐13. ">Bril 1999</a>), the Norfolk Quality of Life‐Diabetic Neuropathy Questionnaire (Norfolk QOL‐DN) (<a href="./references#CD012395-bbs2-0074" title="VinikEJ , HayesRP , OglesbyA , BastyrE , BarlowP , Ford‐MolvikSL , et al. The development and validation of the Norfolk QOL‐DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology &amp; Therapeutics2005;7(3):497‐508. ">Vinik 2005</a>), and composite clinical and neurophysiological evaluations of nerve fiber function, such as the NIS plus 7 nerves test (NIS+7) (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>), have appeared valid and reliable measures of TTR‐FAP severity (<a href="./references#CD012395-bbs2-0026" title="CoelhoT , VinikA , VinikEJ , TrippT , PackmanJ , GroganDR . Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle &amp; Nerve2017;55(3):323‐32. ">Coelho 2017</a>). </p> <section id="CD012395-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012395-list-0004"> <li> <p>Disability due to FAP progression</p> <ul id="CD012395-list-0005"> <li> <p>Expressed as the change from baseline in the:</p> <ul id="CD012395-list-0006"> <li> <p>clinical staging of TTR‐FAP (FAP stage) (<a href="./references#CD012395-bbs2-0027" title="CoutinhoP , Martins da SilvaA , Lopes LimaJ , Resende BarbosaA . Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: GlennerG , CostaP , deFreitasA editor(s). Amyloid and Amyloidosis. Amsterdam: Execerpta Medica, 1980:88‐98. ">Coutinho 1980</a>); </p> </li> <li> <p>Polyneuropathy Disability Score (PDS) (<a href="./references#CD012395-bbs2-0068" title="SteenL , EkB . Familial amyloidosis with polyneuropathy. A long‐term follow‐up of 21 patients with special reference to gastrointestinal symptoms. Acta Medica Scandinavica1983;214:387–97. ">Steen 1983</a>); </p> </li> <li> <p>Modified Norris Test Score (MNT) (<a href="./references#CD012395-bbs2-0042" title="LacomblezL , BoucheP , BensimonG , MeiningerV . A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology1989;39(12):1635–7. ">Lacomblez 1989</a>); </p> </li> <li> <p>Portuguese classification system (PCS) (<a href="./references#CD012395-bbs2-0063" title="Sales‐LuísML , GalvãoM , SousaG , AlvesMM , SerrãoR . Plasma exchanges on: the treatment of familial amyloidotic polyneuropathy, Portuguese type. Familial amyloidotic polyneuropathy and other transthyretin related disorders. Arquivos de Medicina1990;3:361‐9. ">Sales‐Luís 1990</a>); </p> </li> <li> <p>Kumamoto Score (KS) (<a href="./references#CD012395-bbs2-0071" title="TashimaK , AndoY , TerazakiH , YoshimatsuS , SuhrOB , ObayashiK , et al. Outcome of liver transplantation for transthyretin amyloidosis: follow‐up of Japanese familial amyloidotic polyneuropathy patients. Journal of the Neurological Sciences1999;171(1):19‐23. ">Tashima 1999</a>); </p> </li> <li> <p>Yamamoto Score (YS) (<a href="./references#CD012395-bbs2-0076" title="YamamotoS , WilczekH , NowakG , LarssonM , OksanenA , IwataT , et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single‐center experience over 16 years. American Journal of Transplantation2007;7(11):2597–604. ">Yamamoto 2007</a>); and </p> </li> <li> <p>Rasch‐built Overall Disability Scale (R‐ODS) (<a href="./references#CD012395-bbs2-0073" title="vanNesSI , VanhoutteEK , vanDoornPA , HermansM , BakkersM , KuitwaardK , et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology2011;76(4):337‐45. ">van Nes 2011</a>). </p> </li> </ul> </li> </ul> </li> </ul> </p> </section> <section id="CD012395-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012395-list-0007"> <li> <p>Severity of peripheral neuropathy</p> <ul id="CD012395-list-0008"> <li> <p>Expressed as the change from baseline in the:</p> <ul id="CD012395-list-0009"> <li> <p>NIS (<a href="./references#CD012395-bbs2-0031" title="DyckPJ , LitchyWJ , LehmanKA , HokansonJL , LowPA , O'BrienPC . Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology1995;45(6):1115‐21. ">Dyck 1995</a>); </p> </li> <li> <p>NIS‐LL (<a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a>; <a href="./references#CD012395-bbs2-0021" title="BrilV . NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology1999;41(Suppl 1):8‐13. ">Bril 1999</a>); </p> </li> <li> <p>NIS of the Upper Limbs (NIS‐UL) (<a href="./references#CD012395-bbs2-0043" title="LozeronP , ThéaudinM , MinchevaZ , DucotB , LacroixC , AdamsD , French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology2013;20(12):1539‐45. ">Lozeron 2013</a>); </p> </li> <li> <p>NIS+7 (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>) </p> </li> <li> <p>modified versions of NIS+7 (mNIS+7 Alnylam version and mNIS+7 Ionis version) (<a href="./references#CD012395-bbs2-0069" title="SuanprasertN , BerkJL , BensonMD , DyckPJ , KleinCJ , GollobJA , et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences2014;344(1‐2):121‐8. ">Suanprasert 2014</a>; <a href="./references#CD012395-bbs2-0033" title="DyckPJ , KincaidJC , DyckPJ , ChaudhryV , GoyalNA , AlvesC , et al. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle &amp; Nerve2017;56(5):901‐11. ">Dyck 2017</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>); </p> </li> <li> <p>CMT Neuropathy Score (CMTNS) (<a href="./references#CD012395-bbs2-0066" title="ShyME , BlakeJ , KrajewskiK , FuerstDR , LauraM , HahnAF , et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology2005;64(7):1209‐14. ">Shy 2005</a>); </p> </li> <li> <p>CMT Neuropathy Score second version (CMTNS2) (<a href="./references#CD012395-bbs2-0050" title="MurphySM , HerrmannDN , McDermottMP , SchererSS , ShyME , ReillyMM , et al. Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease. Journal of the Peripheral Nervous System2011;16(3):191‐8. ">Murphy 2011</a>) </p> </li> <li> <p>Neuropathy Disability Score revised version (NDS) (<a href="./references#CD012395-bbs2-0016" title="AbbottCA , CarringtonAL , AsheH , BathS , EveryLC , GriffithsJ , et al. The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort. Diabetic Medicine2002;19(5):377‐84. ">Abbott 2002</a>); and </p> </li> <li> <p>Compound Autonomic Dysfunction Test (CADT) (<a href="./references#CD012395-bbs2-0029" title="DenierC , DucotB , HussonH , LozeronP , AdamsD , MeyerL , et al. A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy. Journal of Neurology2007;254(12):1684–8. ">Denier 2007</a>). </p> </li> </ul> </li> </ul> </li> <li> <p>Change in modified body mass index (mBMI)</p> <ul id="CD012395-list-0010"> <li> <p>A measure of wasting and autonomic gastrointestinal function, calculated as the product of the BMI and serum albumin concentration (g/L) (<a href="./references#CD012395-bbs2-0070" title="SuhrO , DanielssonA , HolmgrenG , SteenL . Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. Journal of Internal Medicine1994;235(5):479‐85. ">Suhr 1984</a>), expressed as change from baseline </p> </li> </ul> </li> <li> <p>Quality of life</p> <ul id="CD012395-list-0011"> <li> <p>Expressed as the change from baseline in a validated scale or patient‐reported questionnaire, including the: </p> <ul id="CD012395-list-0012"> <li> <p>36‐Item Short‐Form Health Survey (SF‐36) scale (<a href="./references#CD012395-bbs2-0075" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473–83. ">Ware 1992</a>); </p> </li> <li> <p>Norfolk QOL‐DN (<a href="./references#CD012395-bbs2-0074" title="VinikEJ , HayesRP , OglesbyA , BastyrE , BarlowP , Ford‐MolvikSL , et al. The development and validation of the Norfolk QOL‐DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology &amp; Therapeutics2005;7(3):497‐508. ">Vinik 2005</a>); </p> </li> <li> <p>EuroQoL Quality of Life Scale (EQ‐5D) (<a href="./references#CD012395-bbs2-0056" title="RabinR , deCharroF . EQ‐5D: a measure of health status from the EuroQolGroup. Annals of Medicine2001;33(5):337‐43. ">Rabin 2001</a>); and </p> </li> <li> <p>Karnofsky Performance Status (KPS) (<a href="./references#CD012395-bbs2-0077" title="YatesJW , ChalmerB , McKegneyFP . Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer1980;45:2220–4. ">Yates 1980</a>). </p> </li> </ul> </li> </ul> </li> <li> <p>Severity of depression</p> <ul id="CD012395-list-0013"> <li> <p>Expressed as the change from baseline in a validated scale or clinical diagnostic interview, including the: </p> <ul id="CD012395-list-0014"> <li> <p>Beck Depression Inventory (BDI‐II) (<a href="./references#CD012395-bbs2-0020" title="BeckAT , SteerRA , GarbinMG . Psychometric properties of the Beck Depression Inventory: twenty‐five years of evaluation. Clinical Psychology Review1988;8(1):77‐100. ">Beck 1988</a>); and </p> </li> <li> <p>Hamilton Rating Scale for Depression (HAM‐D) (<a href="./references#CD012395-bbs2-0035" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery &amp; Psychiatry1960;23:56‐62. ">Hamilton 1960</a>). </p> </li> </ul> </li> </ul> </li> <li> <p>Number of participants who died during the trial</p> </li> <li> <p>Adverse events analysed as:</p> <ul id="CD012395-list-0015"> <li> <p>number of participants experiencing at least one adverse event;</p> </li> <li> <p>number of participants experiencing mild adverse events;</p> </li> <li> <p>number of dropouts due to adverse events;</p> </li> <li> <p>number of participants experiencing at least one severe adverse event.</p> </li> </ul> </li> </ul> </p> <p>All outcomes were assessed after 12 and 24 months of treatment (where possible) and at the end of the blinded follow‐up period. We have summarised characteristics of the scores included as primary and secondary outcome measures in <a href="#CD012395-tbl-0005">Table 1</a>. In order not to miss any side effects, in the data extraction phase, we collected all side effects data reported in the literature, and discussed ways to summarise them post hoc. </p> <div class="table" id="CD012395-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Scores included as outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Instrument name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Direction of response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data analysed as</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Stage of disease based on disability or disability</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical staging of TTR‐FAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAP stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0027" title="CoutinhoP , Martins da SilvaA , Lopes LimaJ , Resende BarbosaA . Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: GlennerG , CostaP , deFreitasA editor(s). Amyloid and Amyloidosis. Amsterdam: Execerpta Medica, 1980:88‐98. ">Coutinho 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyneuropathy Disability Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater walking disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0068" title="SteenL , EkB . Familial amyloidosis with polyneuropathy. A long‐term follow‐up of 21 patients with special reference to gastrointestinal symptoms. Acta Medica Scandinavica1983;214:387–97. ">Steen 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Norris Test Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 to 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0042" title="LacomblezL , BoucheP , BensimonG , MeiningerV . A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology1989;39(12):1635–7. ">Lacomblez 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Portuguese classification system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0063" title="Sales‐LuísML , GalvãoM , SousaG , AlvesMM , SerrãoR . Plasma exchanges on: the treatment of familial amyloidotic polyneuropathy, Portuguese type. Familial amyloidotic polyneuropathy and other transthyretin related disorders. Arquivos de Medicina1990;3:361‐9. ">Sales‐Luís 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kumamoto Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0071" title="TashimaK , AndoY , TerazakiH , YoshimatsuS , SuhrOB , ObayashiK , et al. Outcome of liver transplantation for transthyretin amyloidosis: follow‐up of Japanese familial amyloidotic polyneuropathy patients. Journal of the Neurological Sciences1999;171(1):19‐23. ">Tashima 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yamamoto Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0076" title="YamamotoS , WilczekH , NowakG , LarssonM , OksanenA , IwataT , et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single‐center experience over 16 years. American Journal of Transplantation2007;7(11):2597–604. ">Yamamoto 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rasch‐built Overall Disability Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R‐ODS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0073" title="vanNesSI , VanhoutteEK , vanDoornPA , HermansM , BakkersM , KuitwaardK , et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology2011;76(4):337‐45. ">van Nes 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Impairment due to nerve function</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0031" title="DyckPJ , LitchyWJ , LehmanKA , HokansonJL , LowPA , O'BrienPC . Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology1995;45(6):1115‐21. ">Dyck 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score in the lower limbs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS‐LL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0021" title="BrilV . NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology1999;41(Suppl 1):8‐13. ">Bril 1999</a>; <a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score in the upper limbs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS‐UL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0043" title="LozeronP , ThéaudinM , MinchevaZ , DucotB , LacroixC , AdamsD , French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology2013;20(12):1539‐45. ">Lozeron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score plus 7 nerve tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS+7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Neuropathy Impairment Score plus 7 nerve tests (Alnylam version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mNIS+7Alnylam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0069" title="SuanprasertN , BerkJL , BensonMD , DyckPJ , KleinCJ , GollobJA , et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences2014;344(1‐2):121‐8. ">Suanprasert 2014</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Neuropathy Impairment Score plus 7 nerve tests (Ionis version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mNIS+7Ionis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐22.3 to 346.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0069" title="SuanprasertN , BerkJL , BensonMD , DyckPJ , KleinCJ , GollobJA , et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences2014;344(1‐2):121‐8. ">Suanprasert 2014</a>; <a href="./references#CD012395-bbs2-0033" title="DyckPJ , KincaidJC , DyckPJ , ChaudhryV , GoyalNA , AlvesC , et al. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle &amp; Nerve2017;56(5):901‐11. ">Dyck 2017</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Charcot‐Marie Tooth Neuropathy Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMTNS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0066" title="ShyME , BlakeJ , KrajewskiK , FuerstDR , LauraM , HahnAF , et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology2005;64(7):1209‐14. ">Shy 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Charcot‐Marie Tooth Neuropathy Score 2nd version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMTNS2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0050" title="MurphySM , HerrmannDN , McDermottMP , SchererSS , ShyME , ReillyMM , et al. Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease. Journal of the Peripheral Nervous System2011;16(3):191‐8. ">Murphy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Disability Score revised version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rNDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0016" title="AbbottCA , CarringtonAL , AsheH , BathS , EveryLC , GriffithsJ , et al. The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort. Diabetic Medicine2002;19(5):377‐84. ">Abbott 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compound Autonomic Dysfunction Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater autonomic impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0029" title="DenierC , DucotB , HussonH , LozeronP , AdamsD , MeyerL , et al. A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy. Journal of Neurology2007;254(12):1684–8. ">Denier 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Wasting and autonomic gastrointestinal function</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified body mass index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mBMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Product of the BMI (kg/m<sup>2</sup>) </p> <p>and serum albumin concentration (g/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater wasting (worse nutritional status)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0070" title="SuhrO , DanielssonA , HolmgrenG , SteenL . Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. Journal of Internal Medicine1994;235(5):479‐85. ">Suhr 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Quality of life</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short Form 36 Health Survey Questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0075" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473–83. ">Ware 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norfolk Quality of Life–Diabetic Neuropathy Questionnaire<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norfolk QOL‐DN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2 to 138</p> <p>‐4 to 136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0074" title="VinikEJ , HayesRP , OglesbyA , BastyrE , BarlowP , Ford‐MolvikSL , et al. The development and validation of the Norfolk QOL‐DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology &amp; Therapeutics2005;7(3):497‐508. ">Vinik 2005</a> </p> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> </p> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EuroQoL Quality of Life Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQ‐5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0056" title="RabinR , deCharroF . EQ‐5D: a measure of health status from the EuroQolGroup. Annals of Medicine2001;33(5):337‐43. ">Rabin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Karnofsky Performance Status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Karnofsky</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0077" title="YatesJW , ChalmerB , McKegneyFP . Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer1980;45:2220–4. ">Yates 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Depression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beck Depression Inventory 2nd version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDI‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher total scores indicate more severe depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0020" title="BeckAT , SteerRA , GarbinMG . Psychometric properties of the Beck Depression Inventory: twenty‐five years of evaluation. Clinical Psychology Review1988;8(1):77‐100. ">Beck 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamilton Depression Rating Scale for Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HAM‐D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher total scores indicate more severe depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0035" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery &amp; Psychiatry1960;23:56‐62. ">Hamilton 1960</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Slightly different score ranges are reported in different RCTs (range (‐2 to 138) in <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> and range (‐4 to 136) in <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>), although the direction of the scores is the same. </p> </div> </div> </section> </section> </section> <section id="CD012395-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012395-sec-0028"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Neuromuscular Information Specialist searched the following databases on 18 November 2019. </p> <p> <ul id="CD012395-list-0016"> <li> <p>Cochrane Neuromuscular Specialised Register via the Cochrane Register of Studies (CRS‐Web; <a href="./appendices#CD012395-sec-0124">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via CRS‐Web (<a href="./appendices#CD012395-sec-0125">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (1946 to 15 November 2019; <a href="./appendices#CD012395-sec-0126">Appendix 3</a>). </p> </li> <li> <p>Embase (1974 to 15 November 2019; <a href="./appendices#CD012395-sec-0127">Appendix 4</a>). </p> </li> </ul> </p> <p>We did not impose any language restrictions.</p> </section> <section id="CD012395-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all included studies, narrative reviews, and major textbooks on peripheral neuropathies (written in English) for published reports and citations of unpublished research. We also conducted a citation search via the Web of Science (included studies only) on 18 November 2019 to identify additional studies. We contacted known experts in the field via email between 2017 and 2018. We conducted complementary searches on the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp</a>), ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), and ClinicalTrialsRegister.eu (<a href="http://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>) (<a href="./appendices#CD012395-sec-0128">Appendix 5</a>). We reviewed pharmaceutical companies' websites ‐ <a href="http://www.pfizer.com" target="_blank">www.pfizer.com</a>, <a href="http://www.merck.com" target="_blank">www.merck.com</a>, <a href="http://www.ionispharma.com" target="_blank">www.ionispharma.com</a>, and <a href="http://www.alnylam.com" target="_blank">www.alnylam.com</a> ‐ to identify ongoing trials and additional published or unpublished data on 18 November 2019. </p> </section> </section> <section id="CD012395-sec-0030"> <h3 class="title" id="CD012395-sec-0030">Data collection and analysis</h3> <section id="CD012395-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Three review authors (FM, GZ, and ST) independently screened titles and abstracts identified by the electronic searches using <a href="./references#CD012395-bbs2-0028" title="Veritas Health Innovation. Covidence. Melbourne, Australia: Veritas Health Innovation, Version accessed 10 January 2017. ">Covidence</a>. The same review authors obtained the full‐text reports of all potentially eligible studies for independent assessment and suggested studies to be included. All review authors (FM, GMF, LS, FioM, GZ, TC, and ST) agreed on which studies met the inclusion criteria. We resolved any disagreement about inclusion criteria by discussion and consensus. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a 'Characteristics of excluded studies' table (<a href="./references#CD012395-bbs2-0049" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). </p> </section> <section id="CD012395-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (FM and ST) independently extracted data from studies selected for inclusion, using a tailored data collection form. We used '<a href="./references#CD012395-sec-0143" title="">Characteristics of included studies</a>' tables to present the essential features of the included studies. Two other review authors (GMF and TC) checked the data extraction. There were no disagreements on data extraction and entry, which would have been discussed with the remaining authors (LS, FioM, and GZ) if necessary. We contacted trial authors and sponsors for missing data when possible. We extracted the following study characteristics. </p> <p> <ul id="CD012395-list-0017"> <li> <p>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline characteristics, inclusion criteria, and exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported </p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors</p> </li> </ul> </p> <p>One review author (FM) transferred data into Review Manager 5 (<a href="./references#CD012395-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). A second review author (ST) checked the outcome data entries. A third review author (GZ) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD012395-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (FM and ST) independently assessed risk of bias for each study using the Cochrane 'Risk of bias' tool, as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012395-bbs2-0036" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). All review authors (FM, GMF, LS, FioM, GZ, TC, and ST) resolved disagreements by discussion until we reached consensus. We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD012395-list-0018"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We graded studies as having high, low, or unclear risk of bias in each of these domains and provided justifications for our judgements in the 'Risk of bias' tables, with a quote from the study, when appropriate. Where we obtained information on risk of bias from unpublished data, we noted this in the 'Risk of bias' table. </p> </section> <section id="CD012395-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>The primary and secondary outcomes comprised both continuous and dichotomous data. As predetermined in the protocol for this review (<a href="./references#CD012395-bbs2-0078" title="MagrinelliF , FabriziGM , SantoroL , ManganelliF , CavallaroT , ZanetteG , et al. Pharmacological treatment for familial amyloid neuropathy. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012395] ">Magrinelli 2016</a>), we analysed ordinal or continuous data results from measurement scales (<a href="http://archie.cochrane.org/sections/documents/view?version=z1610111517513571843979228647280%26format=REVMAN#TBL-01" target="_blank">Table 1</a>) as continuous variables (disability due to FAP progression, severity of peripheral neuropathy, mBMI, quality of life, severity of depression, and results for mortality and adverse events as dichotomous variables. </p> <section id="CD012395-sec-0035"> <h5 class="title">Continuous data</h5> <p>For continuous data, we provided mean differences (MDs) and 95% confidence intervals (CIs). </p> </section> <section id="CD012395-sec-0036"> <h5 class="title">Dichotomous data</h5> <p>We reported dichotomous data as risk ratios (RRs) with 95% CIs.</p> </section> <section id="CD012395-sec-0037"> <h5 class="title">Skewed and non‐quantitative data</h5> <p>We presented skewed data and non‐quantitative data descriptively.</p> </section> </section> <section id="CD012395-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant, which was also the unit of randomisation in the type of trials that we considered for this review. We took into account the level at which randomisation occurred. </p> </section> <section id="CD012395-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We contacted principal study investigators and sponsors in order to request information about missing data. Where possible, we analysed all outcome measures using an intention‐to‐treat analysis, following the principle 'once randomised always analysed'. We considered and reported if the principle 'last observation carried forward' was used in the included RCTs. </p> </section> <section id="CD012395-sec-0040"> <h4 class="title">Data synthesis</h4> <p>As we were interested in the effects of each drug, we reported the results for each comparison separately and did not perform a meta‐analysis. We did not plan any network meta‐analysis for indirect comparisons of multiple interventions, which would also have been hampered by the use of different measures to assess outcomes in the included RCTs. </p> <section id="CD012395-sec-0041"> <h5 class="title">'Summary of findings' tables</h5> <p>We summarised the main findings of the review using 'Summary of findings' tables according to methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?version=z1610111517513571843979228647280%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). We included the following outcomes. </p> <p> <ul id="CD012395-list-0019"> <li> <p>Disability due to FAP progression</p> </li> <li> <p>Severity of peripheral neuropathy</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Number of participants who died during the trial</p> </li> <li> <p>Adverse events, encompassing:</p> <ul id="CD012395-list-0020"> <li> <p>number of dropouts due to adverse events</p> </li> <li> <p>number of participants experiencing at least one severe adverse event</p> </li> </ul> </li> </ul> </p> <p>Two review authors (FM and ST) worked independently on 'Summary of findings' assessments. Where there were multiple outcome measures among those predetermined for a specific outcome in the protocol of this review, we reported in the 'Summary of findings' tables the one with higher clinical relevance and inter‐rater reproducibility. For instance, among outcome measures assessing the severity of peripheral neuropathy in <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>, we chose to report scores combining clinical and neurophysiological assessments, rather than purely clinical scores. Furthermore, 'Summary of findings' tables report outcome measures at the longest time interval available among those predetermined in the protocol of this review, as this represents the most relevant time interval for people affected by a chronic progressive disease. We used the five <a href="https://archie.cochrane.org/sections/documents/view?version=z1610111517513571843979228647280%26format=REVMAN#REF-GRADEpro-GDT" target="_blank">GRADEpro GDT</a> considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. We downgraded the certainty of studies from high according to whether these considerations are present to a serious degree. We used footnotes to aid the reader's understanding of our judgements where necessary. </p> </section> <section id="CD012395-sec-0042"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice. Our implications for research suggest priorities for future research and outline what the remaining uncertainties are for the topic. </p> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD012395-sec-0141">Differences between protocol and review</a> section of this review. Additional methods for use in future updates, if more trials are available and meta‐analysis becomes possible, are shown in <a href="./appendices#CD012395-sec-0129">Appendix 6</a>. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012395-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012395-sec-0043"></div> <section id="CD012395-sec-0044"> <h3 class="title">Description of studies</h3> <p>See: '<a href="./references#CD012395-sec-0143" title="">Characteristics of included studies</a>' section; '<a href="./references#CD012395-sec-0144" title="">Characteristics of excluded studies</a>' section. </p> <section id="CD012395-sec-0045"> <h4 class="title">Results of the search</h4> <p>We found a total of 719 references from the database search. After deduplication, we screened the resulting 477 references at title and abstract stage. We identified no additional papers by reviewing reference lists of included studies, narrative reviews, and major textbooks on peripheral neuropathies, by conducting a citation search via the Web of Science on 18 November 2019, or through email correspondence with known experts in the field between 2017 and 2018. We selected 147 references for full‐text screening. None of these papers required translation. We also found public synopses of the four identified randomised clinical trials (RCTs) on ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), and of two identified RCTs on ClinicalTrialsRegister.eu (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>) when we conducted complementary searches on clinical trials registers and pharmaceutical company websites. See <a href="#CD012395-fig-0001">Figure 1</a> for a PRISMA flow diagram showing the study selection process for this review. We did not identify any ongoing RCTs that fulfilled our predetermined inclusion criteria. </p> <div class="figure" id="CD012395-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA chart for searched to included studies for FAPs" data-id="CD012395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA chart for searched to included studies for FAPs</p> </div> </div> </div> </section> <section id="CD012395-sec-0046"> <h4 class="title">Included studies</h4> <p>See: '<a href="./references#CD012395-sec-0143" title="">Characteristics of included studies</a>' section. </p> <p>We included four studies, with a total of 655 participants. These studies provided data for four different comparisons. </p> <p> <ul id="CD012395-list-0021"> <li> <p>Tafamidis versus placebo (128 participants; <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>) </p> </li> <li> <p>Diflunisal versus placebo (130 participants; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>) </p> </li> <li> <p>Patisiran versus placebo (225 participants; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>) </p> </li> <li> <p>Inotersen versus placebo (172 participants; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>) </p> </li> </ul> </p> <p>All studies were randomised, double‐blind, multicentre, international trials conducted in outpatient settings. <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> evaluated the efficacy and safety of the transthyretin (TTR) kinetic stabiliser tafamidis 20 mg once daily compared to placebo during 18 months of treatment in adults with early‐stage TTR‐related familial amyloid polyneuropathy (FAP) due to Val30Met mutation in the <i>TTR</i> gene. <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> investigated the efficacy and safety of the TTR kinetic stabiliser diflunisal 250 mg twice daily compared to placebo during 24 months of treatment in adults with TTR‐FAP due to Val30Met and non‐Val30Met mutations in the <i>TTR</i> gene at any stage. <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> explored the efficacy and safety of the TTR small interfering RNA patisiran 0.3 mg/kg once every three weeks compared to placebo after 18 months of treatment in adults with TTR‐FAP due to Val30Met and non‐Val30Met mutations in the <i>TTR</i> gene at any stage, who might previously have received TTR kinetic stabilisers. <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> investigated the efficacy and safety of the TTR antisense oligonucleotide inotersen 300 mg once weekly compared to placebo after 65 weeks of treatment in adults with TTR‐FAP due to Val30Met and non‐Val30Met mutations in the <i>TTR</i> gene at early stages, who might previously have been treated with TTR kinetic stabilisers. <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>, <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>, and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> were funded by the manufacturer of the pharmacological agent under investigation. </p> </section> <section id="CD012395-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 77 full‐text articles that had been considered as possibly eligible for this review at the title and abstract screening stage. In particular, we excluded open‐label extensions of RCTs previously completed. </p> <p>We listed 11 studies of the articles reviewed in full text as <a href="./references#CD012395-bbs1-0002" title="">Excluded studies</a>. These were: </p> <p> <ul id="CD012395-list-0022"> <li> <p>seven non‐randomised studies, of which four were open‐label extension studies involving included interventions (<a href="./references#CD012395-bbs2-0005" title="AdamsD , CoelhoT , ConceicaoI , Waddington CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24‐month safety and efficacy in subgroup of patients with cardiac involvement. European Journal of Heart Failure2017;19(Suppl S1):19. AdamsD , CoelhoT , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran with or without a TTR stabilizer for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. European Journal of Neurology2017;24(Suppl 1):31‐2. AdamsD , CoelhoT , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational RNA interference (RNAi) therapeutic for the treatment of hereditary attr amyloidosis with polyneuropathy. Value in Health2017;20(5):A211‐2. AdamsD , SuhrO , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP). Orphanet Journal of Rare Diseases2015;10:1‐2. ">Adams 2015</a>; <a href="./references#CD012395-bbs2-0007" title="CoelhoT , MaiaLF , daSilvaAM , Waddington‐CruzM , Planté‐BordeneuveV , SuhrOB , et al. Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology2013;260(11):2802‐14. ">Coelho 2013</a>; <a href="./references#CD012395-bbs2-0011" title="DasguptaNR , FalkRH , DrachmanBM , MaurerMS , WhelanCJ , BrannaganT , et al. Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy. Journal of the American College of Cardiology2019;73(9 Suppl 1):909. Plante‐BordeneuveV , BrannaganT , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Long‐term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open‐label extension of the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):30. ">Plante‐Bordeneuve 2018</a>; <a href="./references#CD012395-bbs2-0015" title="Waddington‐CruzM , AmassL , KeohaneD , SchwartzJ , GundapaneniB , LiH . Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P6. Waddington‐CruzM , AmassL , KeohaneD , SchwartzJ , LiH , GundapaneniB . Early intervention with tafamidis provides long‐term (5.5‐year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid2016;23(3):178‐83. Waddington‐CruzM , AmassL , KeohaneDJ , SchwartzJ , LiH , GundapaneniB . Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System2015;20(2):244. ">Waddington‐Cruz 2016</a>), and three were other non‐randomised studies (<a href="./references#CD012395-bbs2-0006" title="BarrosoFA , JudgeDP , EbedeB , LiH , StewartM , AmassL , et al. Long‐term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid2017;24(3):194‐204. ">Barroso 2017</a>; <a href="./references#CD012395-bbs2-0012" title="RussoM , ObiciL , CalabreseD , PiscosquitoG , LuigettiM , ManganelliF , et al. Neurological data collection protocol on tafamidis meglumine treatment for familial amyloid polyneuropathy: Preliminary data on patients enrolled by the Italian network. Journal of the Peripheral Nervous System2013;18:S99. RussoM , StancanelliC , GentileL , ToscanoA , VitaG , MazzeoA . Safety and tolerability of orally administered tafamidis meglumine in TTR FAP: Preliminary data at 3‐month follow‐up. Journal of the Peripheral Nervous System2012;17:S48‐9. ">Russo 2013</a>; <a href="./references#CD012395-bbs2-0014" title="SuhrOB , CoelhoT , BuadesJ , PougetJ , ConceicaoI , BerkJ , et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi‐dose study. Orphanet Journal of Rare Diseases2015;10:109. ">Suhr 2015</a>); </p> </li> <li> <p>one open‐label study of an investigational drug (<a href="./references#CD012395-bbs2-0008" title="GillmoreJD , FalkRH , MaurerMS , HannaM , KarstenV , VestJ , et al. Phase 2, open‐label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Orphanet Journal of Rare Diseases2015;10:1‐2. ">Gillmore 2015</a>); </p> </li> <li> <p>an abstract reporting on drug development (<a href="./references#CD012395-bbs2-0013" title="SahDWY , ChenQ , CostelhaS , ButlerJ , FishmanS , RossomandoA , et al. ALN‐TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis. Nucleic Acid Therapeutics2011;21(5):A55‐6. ">Sah 2011</a>); </p> </li> <li> <p>a paper comparing tamafidis results from a RCT with those of an open‐label study (<a href="./references#CD012395-bbs2-0009" title="GundapaneniB , SultanMB , KeohaneDJ , SchwartzJ . Tafamidis delays disease progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System2017;22(3):294. GundapaneniBK , SultanMB , KeohaneDJ , SchwartzJH . Tafamidis delays disease progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. GundapaneniBK , SultanMB , KeohaneDJ , SchwartzJH . Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. European Journal of Neurology2018;25(3):464‐8. ">Gundapaneni 2018</a>); </p> </li> <li> <p>a RCT of tafamidis focusing on cardiomyopathy, not neuropathy (<a href="./references#CD012395-bbs2-0010" title="MaurerMS , ElliottP , MerliniG , ShahSJ , Waddington‐CruzM , FlynnA , et al. Design and rationale of the phase 3 ATTR‐ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circulation: Heart Failure2017;10(6):e003815. MaurerMS , SchwartzJH , GundapaneniB , PerryM , MerliniG , Waddington‐CruzM , et al. Treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine2018;379(11):1007‐16. ">Maurer 2018</a>). </p> </li> </ul> </p> <p>See: the '<a href="./references#CD012395-sec-0144" title="">Characteristics of excluded studies</a>' section. </p> </section> </section> <section id="CD012395-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>We presented the 'Risk of bias' assessment of each included study in the '<a href="./references#CD012395-sec-0143" title="">Characteristics of included studies</a>' tables. <a href="#CD012395-fig-0002">Figure 2</a> summarises the review authors’ 'Risk of bias' judgments for all included studies. </p> <div class="figure" id="CD012395-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012395-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012395-sec-0049"> <h4 class="title">Allocation</h4> <p>All studies reported methods of randomisation and allocation concealment and we rated them at low risk of bias (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> </section> <section id="CD012395-sec-0050"> <h4 class="title">Blinding</h4> <p>Participants and investigators were blinded to the interventions in <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>, <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>, <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>, and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>, which we rated at low risk of bias. As for the blinding of outcome assessment, we rated three studies at unclear risk of bias (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>), as the statistical analysis of results was conducted by personnel of the sponsor, whereas we rated <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> at low risk of bias. </p> </section> <section id="CD012395-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>, after randomisation of 128 participants, 1/65 (1.5%) in the tafamidis group and 2/63 (3.2%) in the placebo group were excluded from the intention‐to‐treat (ITT) population due to absence of post‐baseline evaluations or genetic testing not confirming TTR‐FAP. <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> then reported a loss to follow‐up of 34/125 (27.2%) participants, with an ITT analysis; we therefore rated this study at high risk of bias. <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> reported 67/130 (51.5%) dropouts and mentioned an ITT analysis which included all randomised participants who initiated treatment, thus being judged at high risk of bias. After reporting that 40/225 (17.8%) participants discontinued the trial regimen and 32/225 (14.2%) were withdrawn from the trial, <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> defined a modified ITT population as all participants who underwent randomisation and received at least one dose of patisiran or placebo; thus, we rated this study at low risk of bias. In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>, one participant in the inotersen group underwent randomisation in error and did not begin the trial regimen. Although <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> mentioned that the efficacy analyses included all randomly‐assigned participants who received at least one dose of a trial regimen and who had at least one post‐baseline efficacy assessment for the mNIS+7 Ionis version or the Norfolk Quality of Life‐Diabetic Neuropathy Questionnaire (Norfolk QOL‐DN) score, there was no clear mention of ITT analysis. We therefore judged this study at unclear risk of bias. </p> </section> <section id="CD012395-sec-0052"> <h4 class="title">Selective reporting</h4> <p>All included studies reported all prespecified outcomes in their published report papers (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>), or public synopses on online clinical trial registries, or both. Therefore, we rated these studies at low risk of bias. </p> </section> <section id="CD012395-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>We rated three studies at unclear risk of other potential sources of bias because of some involvement of the sponsor in the design and conduct of the study (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). We rated <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> at low risk of bias. </p> </section> </section> <section id="CD012395-sec-0054"> <h3 class="title" id="CD012395-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD012395-tbl-0001"><b>Summary of findings for the main comparison</b> Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</a>; <a href="./full#CD012395-tbl-0002"><b>Summary of findings 2</b> Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</a>; <a href="./full#CD012395-tbl-0003"><b>Summary of findings 3</b> Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</a>; <a href="./full#CD012395-tbl-0004"><b>Summary of findings 4</b> Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</a> </p> <p>See: <a href="./full#CD012395-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012395-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012395-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012395-tbl-0004">summary of findings Table 4</a>. </p> <p>Among the included studies, one study investigated tafamidis versus placebo (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>), one study compared diflunisal with placebo (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>), one study explored patisiran versus placebo (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>), and one study examined inotersen versus placebo (<a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). As all included studies investigated a different pharmacological agent compared to placebo, we did not perform a standard pairwise meta‐analysis. We had not planned any network meta‐analysis for indirect comparisons of multiple interventions for this review. The number of studies and available data are currently too limited for formal indirect comparisons to be made between drugs. In addition, they would have been difficult to perform since different measures to assess outcomes were used in the included randomised clinical trials (RCTs). </p> <section id="CD012395-sec-0055"> <h4 class="title">Tafamidis versus placebo in TTR‐FAP</h4> <p>See: <a href="./full#CD012395-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>One study, including 128 randomised participants (intention‐to‐treat (ITT) population, 125 participants) contributed data to the comparison of tafamidis versus placebo (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>). This study followed the principle of 'last observation carried forward'. We obtained data for <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>, both from published report papers and the online trial registries ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and ClinicalTrialsRegister.eu (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>). The predetermined outcomes at time points selected for this review were available at 12 months and at the end of the follow‐up period (18 months) for efficacy outcomes and at the end of the follow‐up period (18 months) for acceptability and tolerability outcomes. As results for continuous variables were available as means ± standard deviations (SDs) for changes within groups and as least‐square mean differences (MDs) ± standard errors (SEs) for differences between groups, we calculated MDs and 95% CIs between groups in Review Manager 5 (<a href="./references#CD012395-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), using available data for changes within groups. </p> <section id="CD012395-sec-0056"> <h5 class="title">Primary outcome measure: disability due to FAP progression</h5> <p><a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> did not report our predetermined primary outcome measure. </p> </section> <section id="CD012395-sec-0057"> <h5 class="title">Secondary outcome measures</h5> <section id="CD012395-sec-0058"> <h6 class="title">Severity of peripheral neuropathy</h6> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (ITT population, N = 125), the severity of peripheral neuropathy, expressed as the change from baseline in the Neuropathy Impairment Score ‐ Lower Limb (NIS‐LL) at 12 months and 18 months was a secondary endpoint. The NIS‐LL ranges from 0 to 88, with higher scores indicating greater deficits (minimum clinically important difference (MCID): 2 points; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 12 months, the mean (standard deviation (SD)) increase from baseline in the NIS‐LL was 1.005 ± 3.964 points in the tafamidis group and 4.835 ± 7.697 points in the placebo group. Therefore, tafamidis may lead to slightly less worsening of peripheral neuropathy compared to placebo (MD ‐3.83 points, 95% confidence interval (CI) ‐5.99 to ‐1.67; P &lt; 0.001; <a href="./references#CD012395-fig-0003" title="">Analysis 1.1</a>), but absolute values of change are small in both groups. At 18 months, the mean (SD) increase from baseline in the NIS‐LL was 2.193 ± 4.372 points in the tafamidis group and 5.402 ± 8.661 points in the placebo group, once again suggesting that there may be slightly less worsening of peripheral neuropathy with tafamidis than with placebo (MD ‐3.21 points, 95% CI ‐5.63 to ‐0.79 points; P = 0.009; low‐certainty evidence; <a href="./references#CD012395-fig-0003" title="">Analysis 1.1</a>). </p> <p>We downgraded the certainty of evidence once for risk of bias as the evidence is from a single study judged at high risk of attrition bias due to its dropout rate, and once for serious imprecision as the evidence is from a single study involving 128 participants and CIs encompass a clinically important effect and little or no effect. The absolute values of change only just exceed the MCID at 12 months and may exceed it at 18 months. </p> </section> <section id="CD012395-sec-0059"> <h6 class="title">Change in modified body mass index (mBMI)</h6> <p><a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (ITT population, N = 125) investigated the change from baseline in the mBMI at 12 months and 18 months as a secondary endpoint. </p> <p>At 12 months, the mean (SD) change from baseline in the mBMI was an increase of 19.4 ± 71.8 kg/m<sup>2</sup> g/L in the tafamidis group and a decrease of 30.8 ± 74.9 kg/m<sup>2</sup> g/L in the placebo group (MD 50.20 kg/m<sup>2</sup> g/L, 95% CI 24.46 to 75.94; P &lt; 0.001; <a href="./references#CD012395-fig-0004" title="">Analysis 1.2</a>). At 18 months, the mean (SD) change from baseline in the mBMI was an increase of 37.9 ± 73.7 kg/m<sup>2</sup> g/L in the tafamidis group and a decrease of 32.7 ± 88.6 kg/m<sup>2</sup> g/L in the placebo group (MD 70.60 kg/m<sup>2</sup> g/L, 95% CI 41.96 to 99.24; P &lt; 0.001; <a href="./references#CD012395-fig-0004" title="">Analysis 1.2</a>). Therefore, at both time points, tafamidis may improve nutritional status compared to placebo. </p> <p>We downgraded the certainty of evidence by one level for risk of bias as the evidence is from a single study judged at high risk of attrition bias due to its dropout rate, and by one level for serious imprecision as the evidence is from a single study involving 128 participants and CIs are wide. Furthermore BMI is an indirect outcome measure potentially influenced by many other aspects of life other than the drug itself. </p> </section> <section id="CD012395-sec-0060"> <h6 class="title">Quality of life</h6> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (ITT population, N = 125), quality of life, expressed as the change from baseline in the 35‐item Norfolk Quality of Life‐Diabetic Neuropathy (QOL‐DN) Questionnaire total score over 12 months was a secondary endpoint; the change over 18 months was a co‐primary endpoint. The Norfolk QOL‐DN total score ranges from ‐2 to 138, with lower scores indicating better quality of life (MCID not provided nor reported in the literature; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 12 months, the mean (SD) increase from baseline in the Norfolk QOL score was 1.10 ± 14.70 points in the tafamidis group and 4.60 ± 19.00 points in the placebo group. At 18 months, the mean (SD) increase from baseline in the Norfolk QOL score was 2.40 ± 14.60 points in the tafamidis group and 6.90 ± 22.90 points in the placebo group. It was therefore, uncertain whether tafamidis leads to any change from baseline of quality of life after 12 months of treatment (MD ‐3.50 points, 95% CI ‐9.48 to 2.48; P = 0.25; <a href="./references#CD012395-fig-0005" title="">Analysis 1.3</a>) and 18 months of treatment (MD ‐4.50 points, 95% CI ‐11.27 to 2.27; P = 0.19; <a href="./references#CD012395-fig-0005" title="">Analysis 1.3</a>) because the certainty of evidence is very low. </p> <p>We downgraded the certainty of evidence by one level for serious risk of bias (as the evidence is from a single study with high risk of attrition bias due to its dropout rate), by one level for serious imprecision (as the evidence is from a single study involving 128 participants and CIs are wide and include the possibility of both harms and benefits), and by one level for serious indirectness (as mechanisms by which this intervention would affect quality of life are not direct). </p> </section> <section id="CD012395-sec-0061"> <h6 class="title">Severity of depression</h6> <p><a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>, did not assess depression using our predetermined outcome measures. </p> </section> <section id="CD012395-sec-0062"> <h6 class="title">Number of participants who died during the trial</h6> <p>According to the published report by Coelho and colleagues (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>), 5 (3.9%) of the 128 randomised participants died during the trial, including 2/65 (3.1%) participants in the tafamidis group and 3/63 (4.8%) participants in the placebo group, with no clear difference between groups (RR 0.65, 95% CI 0.11 to 3.74; P = 0.63; very low‐certainty evidence; <a href="./references#CD012395-fig-0006" title="">Analysis 1.4</a>). In the tafamidis group, one person died from cardiac tamponade after insertion of a pacemaker, and the cause was unknown in another. In the placebo arm, one participant died from sepsis, one from hepatic failure, and one from an unknown cause. The trialists stated that all deaths were a consequence of complications following liver transplantation and none happened during the study or before liver transplantation. </p> <p>There are some discrepancies in mortality results between the published report and results available on ClinicalTrialsRegister.eu (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>). According to the latter, 1/65 (1.5%) participants in the tafamidis group and 3/63 (4.8%) participants in the placebo group died during the trial (RR 0.32, 95% CI 0.03 to 3.02; P = 0.32), with little or no between‐group difference. We received no response to our request for clarification. </p> </section> <section id="CD012395-sec-0063"> <h6 class="title">Adverse events</h6> <section id="CD012395-sec-0064"> <p><b>i) Number of participants experiencing at least one adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (N = 128), 60/65 (92.3%) tafamidis‐treated participants and 61/63 (96.8%) placebo‐treated participants experienced at least one adverse event during the trial, with little or no difference between groups (RR 0.95, 95% CI 0.88 to 1.04; P = 0.26; <a href="./references#CD012395-fig-0007" title="">Analysis 1.5</a>). In the same population, 39/65 (60.0%) tafamidis‐treated participants and 43/63 (68.2%) placebo group participants reported having experienced at least one adverse event related, or possibly related, to the study medication; there was no clear between‐group difference (RR 0.88, 95% CI 0.68 to 1.14; P = 0.33). </p> </section> <section id="CD012395-sec-0065"> <p><b>ii) Number of participants experiencing mild adverse events</b></p> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (N = 128), there was no clear between‐group difference in the number of participants experiencing mild adverse events: 57/65 (87.7%) in the tafamidis group and 56/63 (88.9%) in the placebo group (RR 0.99, 95% CI 0.87 to 1.12; P = 0.83; <a href="./references#CD012395-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD012395-sec-0066"> <p><b>iii) Number of dropouts due to adverse events</b></p> <p><a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (N = 128) reported that 4/65 (6.1%) tafamidis‐treated participants and 3/63 (4.8%) placebo‐treated participants discontinued study medication due to a treatment‐emergent adverse event (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very low‐certainty evidence; <a href="./references#CD012395-fig-0009" title="">Analysis 1.7</a>), which indicated little or no between‐group difference. These adverse events were diarrhoea, nausea, urticaria, and pregnancy (with normal outcome) in the tafamidis group, and paraesthesia associated with fatigue, nausea with unintentional weight loss, and worsening cardiac amyloidosis in the placebo group. </p> </section> <section id="CD012395-sec-0067"> <p><b>iv) Number of participants experiencing at least one severe adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> (N = 128), 6/65 (9.2%) tafamidis‐treated participants and 5/63 (7.9%) placebo‐treated participants experienced at least one serious treatment‐emergent adverse event (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very low‐certainty evidence; <a href="./references#CD012395-fig-0010" title="">Analysis 1.8</a>), indicating no clear difference between groups. The serious adverse events reported in the tafamidis group were urinary tract infections (2 participants), conduction disorder (1 participant), localised infection (1 participant), pneumonia (1 participant), viral infection (1 participant), and urticaria (1 participant). </p> <p>For all outcomes related to mortality and adverse events, we downgraded the certainty of evidence by one level for serious risk of bias (evidence is from a single study judged at high risk of attrition bias due to dropout rate), by two levels for very serious imprecision (there are small event numbers, and CIs include the possibility of both harms and benefits), and by one level for serious indirectness (events were collected by a non‐systematic assessment). </p> </section> </section> </section> </section> <section id="CD012395-sec-0068"> <h4 class="title">Diflunisal versus placebo in TTR‐FAP</h4> <p>See: <a href="./full#CD012395-tbl-0002">summary of findings Table 2</a>. </p> <p>One study, including 130 participants (ITT population) contributed data to the comparison of diflunisal versus placebo (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). This study followed the principle of 'last observation carried forward'. We obtained data for <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> from both published papers and ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). The outcomes preselected for this review were available at 12 months and at the end of the follow‐up period (24 months). Means with 95% CIs for change within groups and MDs with 95% CIs and P values for differences between groups were available for continuous data; therefore, we did not impute missing SDs or SEs. </p> <section id="CD012395-sec-0069"> <h5 class="title">Primary outcome measure: disability due to FAP progression</h5> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130) reported disability due to FAP progression as the change from baseline in the Kumamoto Score (KS) at 12 months and 24 months, as a secondary outcome. The KS ranges from 0 to 102, with higher scores indicating greater disease severity (MCID not provided nor reported in the literature; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 12 months, the mean increase from baseline in the KS was 1.9 points (95% CI 0.1 to 3.7) in the diflunisal group and 4.1 points (95% CI 2.0 to 6.2) in the placebo group, with a MD between groups of ‐2.20 points (95% CI ‐4.91 to 0.51; P = 0.115; <a href="./references#CD012395-fig-0011" title="">Analysis 2.1</a>) corresponding to little or no between‐group difference. At 24 months, the mean increase from baseline in the KS was 3.1 points (95% CI 1.1 to 5.1) in the diflunisal group and 8.0 points (95% CI 5.7 to 10.3) in the placebo group. Therefore, diflunisal may slightly reduce worsening of disability due to FAP progression compared to placebo (MD ‐4.90 points, 95% CI ‐7.89 to ‐1.90; P = 0.002; low‐certainty evidence; <a href="./references#CD012395-fig-0011" title="">Analysis 2.1</a>). </p> <p>We downgraded the certainty of evidence by one level for serious risk of bias (evidence is from a single study judged at high risk of attrition bias due to dropout rate) and by one level for serious imprecision (evidence is from a single study involving 130 participants). </p> </section> <section id="CD012395-sec-0070"> <h5 class="title">Secondary outcome measures</h5> <section id="CD012395-sec-0071"> <h6 class="title">Severity of peripheral neuropathy</h6> <p>In <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130), the primary endpoint was severity of peripheral neuropathy expressed as the change from baseline in the Neuropathy Impairment Score plus 7 nerves test (NIS+7) at 12 months and 24 months. The NIS+7 ranges from 0 to 270, with higher scores indicating greater deficits (MCID: 2 points; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 12 months, the mean increase from baseline in the NIS+7 was 6.2 points (95% CI 2.8 to 9.6) in the diflunisal group and 12.5 points (95% CI 8.6 to 16.4) in the placebo group, with a MD between groups of ‐6.30 points (95% CI ‐11.38 to ‐1.22; P = 0.017; <a href="./references#CD012395-fig-0012" title="">Analysis 2.2</a>), which may slightly favour diflunisal. At 24 months, the mean increase from baseline in the NIS+7 was 8.2 points (95% CI 2.9 to 13.5) in the diflunisal group and 26.3 points (95% CI 20.2 to 32.4) in the placebo group, with a MD between groups of ‐18.10 points (95% CI ‐26.03 to ‐10.17; low‐certainty evidence) favouring diflunisal (P &lt; 0.001; <a href="./references#CD012395-fig-0012" title="">Analysis 2.2</a>). </p> <p>We downgraded the certainty of evidence by one level for serious risk of bias, as the evidence is from a single study judged at high risk of attrition bias due to the dropout rate, and by one level for serious imprecision, as the evidence is from a single study involving 130 participants. </p> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130) also investigated, as secondary endpoints, the severity of peripheral neuropathy with the NIS and the NIS‐LL. The NIS ranges from 0 to 244, with higher scores indicating greater deficits (MCID: 2 points; <a href="#CD012395-tbl-0005">Table 1</a>) and the NIS‐LL ranges from 0 to 88, with higher scores indicating greater deficits (MCID: 2 points; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 12 months, the mean increase from baseline in the NIS was 4.10 points (95% CI 1.30 to 6.90) in the diflunisal group and 10.10 points (95% CI 6.9 to 13.3) in the placebo group, with a MD between groups of ‐6.00 points (95% CI ‐10.17 to ‐1.83; P = 0.006; <a href="./references#CD012395-fig-0013" title="">Analysis 2.3</a>) favouring diflunisal. At 24 months, the mean increase from baseline in the NIS was 6.40 points (95% CI 1.6 to 11.2) in the diflunisal group and 23.20 points (95% CI 17.9 to 28.5) in the placebo group, with a MD between groups of ‐16.80 points (95% CI ‐23.81 to ‐9.78; P &lt; 0.001; <a href="./references#CD012395-fig-0013" title="">Analysis 2.3</a>) in favour of diflunisal. </p> <p>Regarding the NIS‐LL, the mean increase from baseline at 12 months was 3.2 points (95% CI 1.2 to 5.2) in the diflunisal group and 6.0 points (95% CI 3.8 to 8.2) in the placebo group, with a MD between groups of ‐2.80 points (95% CI ‐5.72 to 0.12; P = 0.063; <a href="./references#CD012395-fig-0014" title="">Analysis 2.4</a>), corresponding to little or no between‐group difference. At 24 months, the mean increase from baseline in the NIS‐LL was 3.80 points (95% CI 1.0 to 6.6) in the diflunisal group and 12.10 points (95% CI 8.9 to 15.3) in the placebo group, with a MD between groups of ‐8.30 points (95% CI ‐12.47 to ‐4.13) in favour of diflunisal (P &lt; 0.001; <a href="./references#CD012395-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD012395-sec-0072"> <h6 class="title">Change in modified body mass index (mBMI)</h6> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130) investigated the change from baseline in the mBMI at 12 months and 24 months as secondary endpoints. </p> <p>At 12 months, the mean decrease from baseline in the mBMI was 18.7 kg/m<sup>2</sup> g/L (95% CI ‐51.5 to 14.1) in the diflunisal group and 38.5 kg/m<sup>2</sup> g/L (95% CI ‐74.90 to ‐2.10) in the placebo group. At 24 months, the mean decrease from baseline in the mBMI was 33.7 kg/m<sup>2</sup> g/L (95% CI ‐69.20 to 1.80) in the diflunisal group and 67.9 kg/m<sup>2</sup> g/L (95% CI ‐108.10 to ‐27.70) in the placebo group. There was therefore, no clear between‐group difference in the worsening of nutritional status after 12 months (MD 19.80 kg/m<sup>2</sup> g/L, 95% CI ‐28.27 to 67.87; P = 0.422; <a href="./references#CD012395-fig-0015" title="">Analysis 2.5</a>) and 24 months (MD 34.20 kg/m<sup>2</sup> g/L, 95% CI ‐18.42 to 86.82; P = 0.21; <a href="./references#CD012395-fig-0015" title="">Analysis 2.5</a>). </p> <p>There was serious risk of bias, as the single study has a high risk of attrition bias due to the dropout rate, and very serious imprecision as the evidence is from a single study involving 130 participants and CIs are wide and encompass both a clinically positive and a largely negative effect. Furthermore, this endpoint is indirect (see above). </p> </section> <section id="CD012395-sec-0073"> <h6 class="title">Quality of life</h6> <p>In <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130), the change from baseline in the quality of life measured with the 36‐Item Short‐Form Health Survey (SF‐36) physical component score and SF‐36 mental component score were secondary endpoints. Both scales range from 0 to 100, with lower scores indicating worse status (physical component score MCID: 2 points; mental component score MCID: 3 points; <a href="#CD012395-tbl-0005">Table 1</a>. </p> <p>At 12 months, the mean change from baseline in the SF‐36 physical component score was an increase of 0.7 points (95% CI ‐1.1 to 2.5) in the diflunisal group and a decrease of 1.9 (95% CI ‐3.9 to 0.1) in the placebo group, with a MD between groups of 2.60 (95% CI ‐0.04 to 5.24; P = 0.06; <a href="./references#CD012395-fig-0016" title="">Analysis 2.6</a>), corresponding to an uncertain between‐group difference. At 24 months, the mean change from baseline in the SF‐36 physical component score was an increase of 1.2 points (95% CI ‐1.2 to 3.6) in the diflunisal group and a decrease of 4.9 (95% CI ‐7.6 to ‐2.2) in the placebo group. The MD between groups was 6.10 points (95% CI 2.56 to 9.64; P = 0.001; very low‐certainty evidence; <a href="./references#CD012395-fig-0016" title="">Analysis 2.6</a>), so it was uncertain whether diflunisal improves quality of life. </p> <p>At 12 months, the mean increase from baseline in the SF‐36 mental component score was 2.5 points (95% CI 0.0 to 5.0) in the diflunisal group and 0.8 points (95% CI ‐2.0 to 3.6) in the placebo group. At 24 months, the mean change from baseline in the SF‐36 mental component score was an increase of 3.5 points (95% CI 0.4 to 6.6) in the diflunisal group and a decrease of 0.9 points (95% CI ‐4.4 to 2.6) in the placebo group. Therefore, it was uncertain if diflunisal leads to a change in the SF‐36 mental component score at 12 months (MD 1.70 points, 95% CI ‐1.98 to 5.38; P = 0.37; <a href="./references#CD012395-fig-0017" title="">Analysis 2.7</a>) 24 months (MD 4.40 points, 95% CI ‐0.19 to 8.99; P = 0.063; <a href="./references#CD012395-fig-0017" title="">Analysis 2.7</a>) because the certainty of the evidence is very low. </p> <p>We downgraded the certainty of evidence by one level for serious risk of bias (high risk of attrition bias due to dropout rate), by one level for serious imprecision (CIs include the possibility of both harms and benefits), and by one level for serious indirectness (as mechanisms by which this intervention would affect quality of life are not direct). </p> </section> <section id="CD012395-sec-0074"> <h6 class="title">Severity of depression</h6> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> did not assess depression using our predetermined outcome measures. </p> </section> <section id="CD012395-sec-0075"> <h6 class="title">Number of participants who died during the trial</h6> <p>According to <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>, 13 deaths occurred in the randomised population (N = 130) during the 24‐month study period, including 4 (6.25%) deaths among 64 participants in the diflunisal group and 9 (13.64%) deaths among 66 participants in the placebo group (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very low‐certainty evidence; <a href="./references#CD012395-fig-0018" title="">Analysis 2.8</a>). Therefore, it is uncertain whether diflunisal decreases mortality. Causes of deaths were not reported. The trialists stated that 12/13 (92.3%) deaths occurred after discontinuation of the study medication. </p> <p>We graded the certainty of evidence as very low, downgrading by one level for serious risk of bias (single study at high risk of attrition bias due to dropout rate), two levels for very serious imprecision (small event numbers; and CI includes the possibility of both harms and benefits). </p> </section> <section id="CD012395-sec-0076"> <h6 class="title">Adverse events</h6> <section id="CD012395-sec-0077"> <p><b>i) Number of participants experiencing at least one adverse event</b></p> <p>No data for this outcome were reported in <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>. </p> </section> <section id="CD012395-sec-0078"> <p><b>ii) Number of participants experiencing mild adverse events</b></p> <p>In <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130), it is uncertain whether there were between‐group differences in the number of participants experiencing mild adverse events, with 29/64 (45.3%) in the diflunisal group and 27/66 (40.9%) in the placebo group (RR 1.11, 95% CI 0.75 to 1.65; P = 0.61; <a href="./references#CD012395-fig-0019" title="">Analysis 2.9</a>). </p> </section> <section id="CD012395-sec-0079"> <p><b>iii) Number of dropouts due to adverse events</b></p> <p>In <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130), 4/64 (6.2%) diflunisal‐treated participants and 2/66 (3.0%) placebo‐treated participants discontinued study medication due to treatment‐related adverse events, with a RR of 2.06 (95% CI 0.39 to 10.87; P = 0.39; very low‐certainty evidence; <a href="./references#CD012395-fig-0020" title="">Analysis 2.10</a>). Therefore, it is uncertain whether diflunisal has an effect on treatment discontinuation caused by adverse events. The adverse events that led to discontinuation of the trial regimen were gastrointestinal bleeding, congestive cardiac failure, glaucoma, and nausea in the diflunisal group, and headache and renal failure in the placebo group. </p> </section> <section id="CD012395-sec-0080"> <p><b>iv) Number of participants experiencing at least one severe adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> (N = 130), 3/64 (4.7%) participants in the diflunisal arm and 4/66 (6.1%) participants in the placebo arm discontinued study medication due to treatment‐related adverse events, thus being uncertain whether diflunisal has an effect on severe adverse events (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very low‐certainty evidence; <a href="./references#CD012395-fig-0021" title="">Analysis 2.11</a>). </p> <p>For mortality and available adverse event outcomes, we downgraded the certainty of evidence by one level for serious risk of bias (evidence is from a single study judged at high risk of attrition bias due to the dropout rate) and by two levels for very serious imprecision (single study involving 130 participants; small event numbers; and CIs include the possibility of both harms and benefits). </p> </section> </section> </section> </section> <section id="CD012395-sec-0081"> <h4 class="title">Patisiran versus placebo in TTR‐FAP</h4> <p>See: <a href="./full#CD012395-tbl-0003">summary of findings Table 3</a>. </p> <p>One study (ITT population 225 participants) compared patisiran versus placebo (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). We obtained data for <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> from both published papers and the online trial registries ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and ClinicalTrialsRegister.eu (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>). The outcomes prespecified for this review were only available at the end of the follow‐up period (18 months). Results for continuous variables were provided as least‐square means and SEs for change within groups and least‐square MDs with 95% CIs and P values for differences between groups, and we did not impute any missing mean, SD, MD, or 95% CI. </p> <section id="CD012395-sec-0082"> <h5 class="title">Primary outcome measure: disability due to FAP progression</h5> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225) did not report any of the primary outcome measures described in the protocol of this review. However, it explored disability due to FAP progression, expressed as the change from baseline in the Rasch‐built Overall Disability Scale (R‐ODS) at 18 months, as a secondary outcome. The R‐ODS ranges from 0 to 48, with lower scores indicating greater disability (MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 18 months, the least‐squares mean (SE) change from baseline in the R‐ODS was 0.0 points (0.59) in the patisiran group and ‐8.9 points (0.88) in the placebo group. Therefore, patisiran probably decreases disability due to FAP progression compared to placebo (least‐squares MD 8.90 points, 95% CI 7.00 to 10.80; P &lt; 0.001; moderate‐certainty evidence; <a href="./references#CD012395-fig-0022" title="">Analysis 3.1</a>). </p> <p>We downgraded the certainty of evidence by one level for serious imprecision, as evidence is from a single study including 225 participants. </p> </section> <section id="CD012395-sec-0083"> <h5 class="title">Secondary outcome measures</h5> <section id="CD012395-sec-0084"> <h6 class="title">Severity of peripheral neuropathy</h6> <p>In <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225), the severity of peripheral neuropathy, expressed as the change from baseline in the modified Neuropathy Impairment Score plus 7 nerves test (mNIS+7ALN) was the primary efficacy endpoint. The scale ranges from 0 to 304, with higher scores indicating greater deficits (MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>) . </p> <p>At 18 months, the least‐squares mean (SE) change from baseline in the mNIS+7ALN was a decrease of 6.03 points (1.74) in the patisiran group and an increase of 27.96 points (2.60) in the placebo group. The least‐squares MD between groups was ‐33.99 points (95% CI ‐39.86 to ‐28.12; P &lt; 0.001; moderate‐certainty evidence; <a href="./references#CD012395-fig-0023" title="">Analysis 3.2</a>). This indicates that peripheral neuropathy probably worsened slightly less with patisiran than placebo. </p> <p>We downgraded the certainty of evidence by one level for serious imprecision, as evidence is from a single study including 225 participants. </p> </section> <section id="CD012395-sec-0085"> <h6 class="title">Change in modified body mass index (mBMI)</h6> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225) investigated the change from baseline in the mBMI at 18 months as a secondary endpoint. </p> <p>At 18 months, the least‐squares mean (SE) decrease from baseline in the mBMI was 3.7 kg/m<sup>2</sup> g/L (9.57) in the patisiran group and 119.4 kg/m<sup>2</sup> g/L (14.51) in the placebo group, with a least‐squares MD between groups of 115.70 kg/m<sup>2</sup> g/L (95% CI 82.40 to 149.00; P &lt; 0.001; <a href="./references#CD012395-fig-0024" title="">Analysis 3.3</a>), indicating that nutritional status probably worsened less in patisiran‐treated participants than the placebo group. </p> <p>We downgraded the certainty of evidence by one level for serious imprecision, as the evidence is from a single study involving 225 participants, and CIs are wide. </p> </section> <section id="CD012395-sec-0086"> <h6 class="title">Quality of life</h6> <p>The quality of life, expressed as the change from baseline in the Norfolk QOL‐DN total score was a secondary endpoint in <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225). The scale ranges from ‐4 to 136, with lower scores indicating better quality of life (MCID not provided nor reported in the literature; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At 18 months, the least‐squares mean (SE) change from baseline in the Norfolk QOL‐DN total score was a decrease of 6.7 points (1.77) in the patisiran group and an increase of 14.4 (2.73) in the placebo group (least‐squares MD ‐21.10 points, 95% CI ‐27.20 to ‐15.00; P &lt; 0.001; low‐certainty evidence; <a href="./references#CD012395-fig-0025" title="">Analysis 3.4</a>). This indicates that quality of life may decline slightly less with patisiran than placebo. </p> <p>We downgraded the certainty of evidence by one level for serious imprecision (sample size is below 400) and by one level for serious indirectness (mechanisms by which this intervention would affect quality of life are not direct). </p> </section> <section id="CD012395-sec-0087"> <h6 class="title">Severity of depression</h6> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> did not assess depression using our predetermined outcome measures. </p> </section> <section id="CD012395-sec-0088"> <h6 class="title">Number of participants who died during the trial</h6> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> reported 13 (5.8%) deaths in the randomised population out of 225 participants during the 18‐month study period, including seven (4.7%) deaths in the patisiran group (148 participants) and six (7.8%) deaths in the placebo group (77 participants) (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; low‐certainty evidence; <a href="./references#CD012395-fig-0026" title="">Analysis 3.5</a>). There may therefore, be little or no difference in mortality in participants treated with patisiran compared to those who received placebo. In the patisiran‐treated population, two deaths occurred as a consequence of cardiac arrest, two due to sudden cardiac death (one of which after more than 30 days off treatment), two due to cardiac failure, and one due to pulseless electrical activity. In the placebo group, causes of deaths were subarachnoid haemorrhage, staphylococcal sepsis, anaemia associated with gastrointestinal haemorrhage, acute kidney failure associated with urinary tract infection and bacteraemia, metastatic colorectal cancer, and ischaemic stroke. The investigators considered all deaths unlikely or not related to the intervention drug. </p> </section> <section id="CD012395-sec-0089"> <h6 class="title">Adverse events</h6> <section id="CD012395-sec-0090"> <p><b>i) Number of participants experiencing at least one adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225), 143/148 (96.6%) patisiran‐treated participants and 75/77 (97.4%) placebo group participants experienced at least one adverse event (RR 0.99, 95% CI 0.95 to 1.04; P = 0.74; <a href="./references#CD012395-fig-0027" title="">Analysis 3.6</a>), with no clear between‐group difference. </p> </section> <section id="CD012395-sec-0091"> <p><b>ii) Number of participants experiencing mild adverse events</b></p> <p>There was not enough detail to impute the prevalence of mild adverse events among all adverse events reported. </p> </section> <section id="CD012395-sec-0092"> <p><b>iii) Number of dropouts due to adverse events</b></p> <p>In <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225), 7/148 (4.7%) patisiran‐treated participants and 11/77 (14.3%) placebo‐treated participants were reported to have discontinued study medication due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; low‐certainty evidence; <a href="./references#CD012395-fig-0028" title="">Analysis 3.7</a>). The most frequent adverse events that led to discontinuation of the trial regimen were cardiac failure in the patisiran group (2/148 participants, 1.3%) and acute kidney injury in the placebo group (3/77 participants, 3.9%). For the same RCT, the online trial registries ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and ClinicalTrialsRegister.eu (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>) reported that 8/148 (5.4%) patisiran‐treated participants and 10/77 (13.0%) placebo‐treated participants discontinued study medication due to adverse events (RR 0.42, 95% CI 0.17 to 1.01; P = 0.05). Although we were unable to clarify this discrepancy, this study provides evidence that there may be no clear difference in dropouts due to adverse events with patisiran compared to placebo. </p> </section> <section id="CD012395-sec-0093"> <p><b>iv) Number of participants experiencing at least one severe adverse event</b></p> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 225) reported that 54/148 (36.5%) patisiran‐treated participants and 31/77 (40.3%) placebo group participants experienced at least one serious adverse event during the study (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; low‐certainty evidence; <a href="./references#CD012395-fig-0029" title="">Analysis 3.8</a>), thus suggesting that patisiran may lead to little or no difference in the incidence of severe adverse events. The most frequent severe adverse events reported in the patisiran group (N = 148) were diarrhoea (8 participants, 5.4%), cardiac failure (6 participants, 4.0%), pneumonia (3 participants, 2.0%), orthostatic hypotension (3 participants, 2.0%), and complete atrioventricular block (3 participants, 2.0%). </p> <p>For all outcomes related to mortality and adverse events, we downgraded the certainty of evidence by two levels for very serious imprecision, as evidence is provided by a single study involving 225 participants, there are small event numbers, and CIs include the possibility of both harms and benefits. </p> </section> </section> </section> </section> <section id="CD012395-sec-0094"> <h4 class="title">Inotersen versus placebo in TTR‐FAP</h4> <p>See: <a href="./full#CD012395-tbl-0004">summary of findings Table 4</a>. </p> <p>One study, including 172 participants (ITT population) contributed data to the comparison of inotersen versus placebo (<a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). We obtained information on results of <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> from both published papers and the online trial registry ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). The predetermined outcomes at time points selected for this review were available at the end of the follow‐up period (65 to 66 weeks) only. Results for continuous variables were provided both as means ± standard deviations (SDs) and least‐square means and SEs for change within groups, and as least‐square MDs and 95% CIs for differences between groups. We therefore calculated MDs and 95% CIs between groups in Review Manager 5 (<a href="./references#CD012395-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), entering values of means ± SDs available for changes within groups. </p> <section id="CD012395-sec-0095"> <h5 class="title">Primary outcome measure: disability due to FAP progression</h5> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> did not report our predetermined primary outcome measure. </p> </section> <section id="CD012395-sec-0096"> <h5 class="title">Secondary outcome measures</h5> <section id="CD012395-sec-0097"> <h6 class="title">Severity of peripheral neuropathy</h6> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172), the severity of peripheral neuropathy, expressed as the change from baseline in the modified Neuropathy Impairment Score plus 7 nerves test (Ionis version) (mNIS+7Ionis) was one of the primary efficacy endpoints. The mNIS+7Ionis ranges from ‐22.3 to 346.3, with higher scores indicating greater deficits (MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At week 66, the mean increase (SD) from baseline in the mNIS+7Ionis score was 4.16 ± 15.672 points in the inotersen group and 23.89 ± 24.19 points in the placebo group. The MD between groups was ‐19.73 (95% CI ‐26.5 to ‐12.96; P &lt; 0.001; moderate‐certainty evidence; <a href="./references#CD012395-fig-0030" title="">Analysis 4.1</a>). This indicated that peripheral neuropathy worsened slightly less with inotersen than with placebo. </p> <p>We downgraded the certainty of evidence by one level for serious imprecision, as evidence is from a single study involving 172 participants. </p> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172) also investigated the severity of peripheral neuropathy with other outcome measures, whose ranges did not correspond to the scales predetermined in the protocol of this review for this outcome. </p> </section> <section id="CD012395-sec-0098"> <h6 class="title">Change in modified body mass index (mBMI)</h6> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172) provided data on the change from baseline in the mBMI at week 65 as a secondary endpoint. </p> <p>At week 65, the mean (SD) decrease from baseline in the mBMI was 73.32 ± 96.31 kg/m<sup>2</sup> g/L in the inotersen group and 85.21 ± 91.26 kg/m<sup>2</sup> g/L in the placebo group, thus revealing no clear between‐group difference in effect on nutritional status (MD 11.89 kg/m<sup>2</sup> g/L, 95% CI ‐17.29 to 41.07; P = 0.43; <a href="./references#CD012395-fig-0031" title="">Analysis 4.2</a>). </p> <p>We downgraded the certainty of evidence by one level for serious imprecision, as evidence is from a single study involving 172 participants. </p> </section> <section id="CD012395-sec-0099"> <h6 class="title">Quality of life</h6> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172), the quality of life, expressed as the change from baseline in the Norfolk QOL‐DN total score was a primary efficacy endpoint. This scale has a range of ‐4 to 136, with lower scores indicating better quality of life (MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>). </p> <p>At week 66, the mean (SD) change from baseline in the Norfolk QOL‐DN total score was a decrease of 0.08 ± 18.97 points in the inotersen group and an increase of 10.77 ± 21.13 points in the placebo group, with a MD between groups of ‐10.85 points (95% CI ‐17.25 to ‐4.45; low‐certainty evidence) favouring inotersen (P &lt; 0.001; <a href="./references#CD012395-fig-0032" title="">Analysis 4.3</a>). </p> <p>We downgraded the certainty of evidence by one level for serious imprecision (sample size is below 400) and by one level for serious indirectness (mechanisms by which this intervention would affect quality of life are not direct). </p> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N =172) also reported the change from baseline in the SF‐36 physical component score as a measure of quality of life and a tertiary outcome. The SF‐36 physical component scale ranges from 0 to 100, with lower scores indicating worse status (MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>). At week 66, the least‐squares mean decrease (SE) from baseline in the SF‐36 physical component score was 0.05 points (0.80) in the inotersen group and 3.65 points (1.01) in the placebo group, with a least‐squares MD of ‐3.60 points (95% CI ‐6.13 to ‐1.07; P = 0.005; <a href="./references#CD012395-fig-0033" title="">Analysis 4.4</a>) favouring inotersen. </p> </section> <section id="CD012395-sec-0100"> <h6 class="title">Severity of depression</h6> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> did not assess depression using our predetermined outcome measures. </p> </section> <section id="CD012395-sec-0101"> <h6 class="title">Number of participants who died during the trial</h6> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>, five deaths occurred in the ITT population (172 participants) during the trial, all in the inotersen group (5/112, 4.5%), with a RR of 5.94 (95% CI 0.33 to 105.60; P = 0.22; low‐certainty evidence; <a href="./references#CD012395-fig-0034" title="">Analysis 4.5</a>). Among these, one participant died as a consequence of intracranial haemorrhage in association with very severe thrombocytopenia (platelet count &lt; 25,000 per cubic millilitre), possibly related to the interventional drug, whereas four deaths were consistent with progression or complication of TTR‐FAP (2 deaths due to cachexia, 1 due to intestinal perforation, and 1 due to congestive heart failure). </p> </section> <section id="CD012395-sec-0102"> <h6 class="title">Adverse events</h6> <section id="CD012395-sec-0103"> <p><b>i) Number of participants experiencing at least one adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172), 111/112 (99.1%) inotersen‐treated participants and 60/60 (100%) placebo‐treated participants experienced at least one adverse event (RR 0.99, 95% CI 0.96 to 1.03; P = 0.75; <a href="./references#CD012395-fig-0035" title="">Analysis 4.6</a>). In the same population, 87/112 (77.7%) tafamidis‐treated participants and 23/60 (38.3%) placebo‐treated participants reported having experienced at least one adverse event that was considered by the investigators to be related, or possibly related, to the study medication, with a RR of 2.03 (95% CI 1.45 to 2.84; P &lt; 0.001; <a href="./references#CD012395-fig-0036" title="">Analysis 4.7</a>). </p> </section> <section id="CD012395-sec-0104"> <p><b>ii) Number of participants experiencing mild adverse events</b></p> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> (N = 172) reported that 110/112 (98.2%) participants in the inotersen group and 60/60 (100.0%) participants in the placebo group experienced mild adverse events (RR 0.99, 95% CI 0.95 to 1.02; P = 0.44; <a href="./references#CD012395-fig-0037" title="">Analysis 4.8</a>), thus showing little or no difference between groups. </p> </section> <section id="CD012395-sec-0105"> <p><b>iii) Number of dropouts due to adverse events</b></p> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172), 16/112 (14.3%) inotersen‐treated participants and 1/60 (1.7%) placebo‐treated participants discontinued study medication due to treatment‐emergent adverse events, with a RR of 8.57 (95% CI 1.16 to 63.07; P = 0.035; low‐certainty evidence; <a href="./references#CD012395-fig-0038" title="">Analysis 4.9</a>), suggesting that inotersen may increase the number of dropouts due to adverse events. These were thrombocytopenia, abdominal distension, intestinal perforation, nausea, vomiting, pyrexia, hypersensitivity, cachexia, arthralgia, myalgia, chorea, dementia, embolic stroke, intracranial haemorrhage, myelopathy, myoclonus, acute kidney injury, glomerulonephritis, tubulointerstitial nephritis, pruritus, reticular erythematous mucinosis, and deep vein thrombosis in the inotersen group, and pain, increased weight, and arthralgia in the placebo arm. </p> </section> <section id="CD012395-sec-0106"> <p><b>iv) Number of participants experiencing at least one severe adverse event</b></p> <p>In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> (N = 172), 36/112 (32.1%) inotersen‐treated participants and 13/60 (21.7%) placebo‐treated participants experienced at least one severe adverse event (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low‐certainty evidence; <a href="./references#CD012395-fig-0039" title="">Analysis 4.10</a>). In the same population, 8/112 (7.1%) inotersen‐treated participants and 1/60 (1.7%) placebo‐treated participants experienced at least one severe adverse event that was considered by the investigators to be related or possibly related to study medication, with a RR of 4.29 (95% CI 0.55 to 33.46; P = 0.16; <a href="./references#CD012395-fig-0040" title="">Analysis 4.11</a>). The most frequent severe adverse events in the inotersen group (N = 112) were glomerulonephritis (3 participants, 2.7%), which caused permanent haemodialysis in one participant (0.9%), and very marked thrombocytopenia (3 participants, 2.7%), which was responsible for an intracranial haemorrhage, leading to death in one participant. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012395-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012395-sec-0107"></div> <section id="CD012395-sec-0108"> <h3 class="title" id="CD012395-sec-0108">Summary of main results</h3> <p>Four randomised controlled trials (RCTs) with a total of 655 randomised participants with transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) were eligible for inclusion in this review. The four comparisons in the included studies were: 1) tafamidis versus placebo (1 study, 128 participants), 2) diflunisal versus placebo (1 study, 130 participants), 3) patisiran versus placebo (1 study, 225 participants), and 4) inotersen versus placebo (1 study, 172 participants). We did not find any study that looked at pharmacological treatment for people with apolipoprotein AI‐FAP, gelsolin‐FAP, or beta‐2‐microglobulin‐FAP. </p> <p>Two studies explored disability due to FAP progression using our prespecified measures (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> suggested that diflunisal might reduce progression of disability (Kumamoto Score) compared to placebo, whereas <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> reported that patisiran probably slightly decreased disability due to FAP progression compared to placebo (Rasch‐built Overall Disability Scale). </p> <p>All included RCTs investigated the change from baseline in severity of peripheral neuropathy, through different measures of nerve impairment (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). The results of <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> suggested that tafamidis might reduce progression of peripheral neuropathy compared to placebo, documented by the Neuropathy Impairment Score in the Lower Limbs (NIS‐LL). Evidence from <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> indicated that diflunisal might reduce worsening of peripheral neuropathy compared to placebo, measured on the NIS plus 7 nerve tests (NIS+7). According to <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>, patisiran reduced progression of peripheral neuropathy compared to placebo, measured on the modified NIS+7 Alnylam version. Inotersen reduced worsening of peripheral neuropathy compared to placebo, measured on the mNIS+7 Ionis version (<a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> <p>All the included studies assessed the change from baseline in quality of life on different scales (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). Quality of life was an indirect measure of the drug function and could be influenced by many factors. There was little or no difference in the change of quality of life with tafamidis in comparison to placebo (according to the Norfolk QOL‐DN total score; <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>) and no clear difference between diflunisal and placebo (as measured by the 36‐Item Short‐Form Health Survey (SF‐36) physical component and mental component scores; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). In <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>, patisiran (measured on the Norfolk QOL‐DN total score) and inotersen favoured quality of life compared to placebo, respectively. </p> <p>For tafamidis (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>) and diflunisal (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>), no clear differences compared to placebo were found in the numbers of participants who died, who dropped out due to adverse events, and who experienced at least one severe adverse event. </p> <p>According to <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>, there may be little or no difference in mortality, dropouts due to adverse events, or number of people experiencing severe adverse events between participants who received patisiran compared to those who received placebo. In <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>, data indicated that there may be a higher number of deaths and of participants with severe adverse events in the inotersen group than in the placebo group, and revealed that there may be more dropouts due to adverse events with inotersen compared to placebo. In particular, three cases of glomerulonephritis and three cases of thrombocytopenic intracranial haemorrhage were reported. </p> </section> <section id="CD012395-sec-0109"> <h3 class="title" id="CD012395-sec-0109">Overall completeness and applicability of evidence</h3> <p>This review primarily assessed whether any disease‐modifying pharmacological treatment reduced disability due to FAP progression in people with TTR‐FAP. It also evaluated other parameters, such as severity of peripheral neuropathy, modified body mass index (mBMI), quality of life, severity of depression, and safety (number of deaths during the trial, number of participants with at least one adverse event, number of participants with mild adverse events, dropouts due to adverse events, and number of participants with at least one severe adverse event). </p> <p><a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> examined tafamidis versus placebo only for the treatment of early‐stage TTR‐FAP due to Val30Met mutation in the <i>TTR</i> gene. <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>, <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>, and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> investigated, respectively, diflunisal, patisiran, and inotersen versus placebo in people with TTR‐FAP at any stage due to either Val30Met or non‐Val30Met mutation in the <i>TTR</i> gene. </p> <p>Only two of the included studies provided data for the primary outcome of this review using our predetermined outcome measures (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). All included studies evaluated the severity of peripheral neuropathy and the change from baseline in the quality of life using different outcome measures or slightly different score range for the same outcome measure (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). All included studies explored the change from baseline in the mBMI as a measure of the nutritional status/global wasting (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). None of the included studies reported a specific evaluation of depression. All included studies provide evidence for safety and tolerability (mortality and adverse events) (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> <p>We reported results for people with TTR‐FAP only, as we found no evidence on pharmacological treatment of ApoAI‐FAP, Gel‐FAP, and B2M‐FAP in the current literature. </p> <p>The number of studies and available data are currently too limited for formal indirect comparisons to be made between drugs, which would also have been hampered by the use of different outcome measures in the included studies. </p> <section id="CD012395-sec-0110"> <h4 class="title">Certainty of the evidence</h4> <p>Data for disability due to FAP progression were available only for diflunisal and patisiran (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). Evidence for the effects of diflusinal and patisiran versus placebo on disability due to FAP progression was of low and moderate certainty, respectively (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). We downgraded the certainty of evidence for both comparisons by one level due to serious imprecision as data were from single studies with small sample sizes (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). In addition, we downgraded the certainty of evidence for the comparison between diflunisal and placebo by one level due to serious risk of bias since data were from a single study which we judged to be at high risk of attrition bias due to its dropout rate (<a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). </p> <p>All included RCTs investigated the effects of a drug (tamafidis, diflunisal, patisiran or inotersen) on the change in the severity of peripheral neuropathy compared to placebo (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). We downgraded the certainty of evidence for this outcome to low for tafamidis and diflunisal (serious risk of bias in the single RCTs included in these comparisons and serious imprecision; <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). We downgraded the certainty of evidence for this outcome to moderate for patisiran and inotersen as data were from single studies with small sample sizes (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> <p>Data on quality of life were available for all four drugs in comparison with placebo (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). The certainty of evidence for this outcome was very low for tafamidis and diflunisal as we downgraded the certainty of evidence by one level for risk of bias, by one level for serious imprecision, and by one level for serious indirectness (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). We downgraded the certainty of evidence twice for patisiran and inotersen: once for serious imprecision due to small sample size and once for serious indirectness, because the interventions would affect quality of life only by indirect mechanisms (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> <p>Data for mortality, dropouts, and adverse events were available for all four treatments (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). We downgraded the certainty of evidence for tafamidis and diflunisal to very low for mortality, dropouts due to adverse events and severe adverse events due to serious risk of bias and very serious imprecision (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>; <a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a>). For patisiran and inotersen, we downgraded the certainty of evidence for these outcomes by two levels for very serious imprecision due to small sample sizes, small event numbers, and wide CIs, which in some cases include the possibility of both harms and benefits, which made findings of low certainty (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>). </p> </section> </section> <section id="CD012395-sec-0111"> <h3 class="title" id="CD012395-sec-0111">Potential biases in the review process</h3> <p>We are confident that we have identified all relevant studies in this review as this is a small, albeit growing field and we supplemented our search strategy with checking references, searching online clinical trial registries, and contacting experts in the field. We followed standard methodological procedures to reduce bias in the review process and we adhered to the inclusion and exclusion criteria prespecified in the protocol in order to limit subjectivity (New Reference). In addition, the fact that there was almost complete consensus between review authors responsible for study selection suggests that the risk of selection bias in this part of the review process was probably low. We made efforts to trace study authors and additional data from manufacturers in order to clarify minor discrepancies in data obtained from published report papers and online clinical trial registries, but we were unable to do so. If we can source supplementary data, we will consider them in future updates. It should be noted that reviews that include a small number of trials, such as ours, have limitations in relation to events that occur infrequently, such as adverse events. We also consider a limitation of this review that we did not plan a network meta‐analysis to compare different pharmacological agents; however this would not have been possible with currently available trials. </p> </section> <section id="CD012395-sec-0112"> <h3 class="title" id="CD012395-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review on pharmacological treatments for FAPs. </p> <section id="CD012395-sec-0113"> <h4 class="title">Open‐label extensions of previously completed RCTs and minor evidence for pharmacological agents not investigated in RCTs </h4> <p>We briefly summarise below evidence from open‐label extensions of the RCTs included in this review and minor evidence regarding pharmacological agents not previously investigated in RCTs. </p> <section id="CD012395-sec-0114"> <h5 class="title">Tafamidis</h5> <p>In a 12‐month open‐label extension study of tafamidis (NCT00791492; <a href="./references#CD012395-bbs2-0007" title="CoelhoT , MaiaLF , daSilvaAM , Waddington‐CruzM , Planté‐BordeneuveV , SuhrOB , et al. Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology2013;260(11):2802‐14. ">Coelho 2013</a>), 86 people with TTR‐FAP who completed the pivotal study of tafamidis were enrolled (<a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a>), of whom 85 either continued on tafamidis 20 mg once daily (44 participants) or were switched from placebo to tafamidis 20 mg once daily (41 participants). This study did not assess disability due to FAP progression using our predetermined outcome measures. At 12 months, the mean (standard deviation (SD)) increase from baseline in the NIS‐LL (range: 0 to 88, with higher scores indicating greater deficits; minimum clinically important difference (MCID): 2 points; <a href="#CD012395-tbl-0005">Table 1</a>) was 1.36 ± 4.77 points in participants who continued on tafamidis and 1.6 ± 8.2 points in participants switched from placebo to tafamidis. At the same time point, the mean (SD) change from baseline in the mBMI was a decrease of 0.12 ± 1.16 kg/m<sup>2</sup> g/L in the tafamidis‐tafamidis group and an increase of 0.73 ± 1.45 kg/m<sup>2</sup> g/L in the placebo‐tafamidis group. After 12 months, the mean (SD) change from baseline in the Norfolk‐QOL total score (range: ‐2 to 138, with lower scores indicating better quality of life; MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>) was an increase of 2.25 ± 8.91 points in participants who continued on tafamidis and a decrease of 2.33 ± 15.66 points in participants switched from placebo to tafamidis. No participants died or discontinued treatment due to an adverse event during this study. In <a href="./references#CD012395-bbs2-0007" title="CoelhoT , MaiaLF , daSilvaAM , Waddington‐CruzM , Planté‐BordeneuveV , SuhrOB , et al. Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology2013;260(11):2802‐14. ">Coelho 2013</a>, 5/44 (11.4%) participants in the tafamidis‐tafamidis group and 4/41 (9.8%) participants in the placebo‐tafamidis group experienced one severe adverse event, whereas 24/44 (54.5%) participants who continued on tafamidis and 24/41 (58.5%) participants who were switched from placebo to tafamidis had at least one mild adverse event. </p> <p>An open‐label, multicentre, international study investigated tafamidis 20 mg once daily for 12 months in people with non‐Val30Met TTR‐FAP (NCT00630864; <a href="./references#CD012395-bbs2-0048" title="MerliniG , Planté‐BordeneuveV , JudgeDP , SchmidtH , ObiciL , PerliniS , et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non‐Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research2013;6(6):1011‐20. ">Merlini 2013</a>). This study did not assess disability due to FAP progression using our predetermined outcome measures. At 12 months, the mean (SD) increase from baseline in the NIS‐LL (range: 0 to 88, with higher scores indicating greater deficits; MCID: 2 points; <a href="#CD012395-tbl-0005">Table 1</a>) was 2.7 ± 6.21 points. At the same time point, the mean (SD) increase from baseline in the mBMI was 16.6 ± 89.33 kg/m<sup>2</sup> g/L. After 12 months, the mean (SD) change from baseline in the Norfolk‐QOL total score (range: ‐2 to 138, with lower scores indicating better quality of life; MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>) was an increase of 0.1 ± 18.01 points. No participant died during this study. In <a href="./references#CD012395-bbs2-0048" title="MerliniG , Planté‐BordeneuveV , JudgeDP , SchmidtH , ObiciL , PerliniS , et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non‐Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research2013;6(6):1011‐20. ">Merlini 2013</a>, 17/21 (80.9%) participants experienced at least one adverse event, 13/21 (61.9%) participants had a mild adverse event, 1/21 (4.8%) discontinued due to an adverse event, and 8/21 (38.1%) participants were reported to have severe adverse events. </p> <p>An ongoing, not recruiting, open‐label extension study of tafamidis was designed to obtain additional, long‐term efficacy and safety data on tafamidis 20 mg once daily over a 10‐year period and was initiated in 2009 (NCT00925002; <a href="./references#CD012395-bbs2-0015" title="Waddington‐CruzM , AmassL , KeohaneD , SchwartzJ , GundapaneniB , LiH . Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P6. Waddington‐CruzM , AmassL , KeohaneD , SchwartzJ , LiH , GundapaneniB . Early intervention with tafamidis provides long‐term (5.5‐year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid2016;23(3):178‐83. Waddington‐CruzM , AmassL , KeohaneDJ , SchwartzJ , LiH , GundapaneniB . Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System2015;20(2):244. ">Waddington‐Cruz 2016</a>; <a href="./references#CD012395-bbs2-0006" title="BarrosoFA , JudgeDP , EbedeB , LiH , StewartM , AmassL , et al. Long‐term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid2017;24(3):194‐204. ">Barroso 2017</a>). It enrolled 93 people with TTR‐FAP who had completed the 12‐month open‐label extension study of tafamidis (NCT00791492; <a href="./references#CD012395-bbs2-0007" title="CoelhoT , MaiaLF , daSilvaAM , Waddington‐CruzM , Planté‐BordeneuveV , SuhrOB , et al. Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology2013;260(11):2802‐14. ">Coelho 2013</a>) or the open‐label study to evaluate TTR stabilisation, safety, tolerability, and efficacy of tafamidis in participants with non‐Val30Met TTR‐FAP (NCT00630864; <a href="./references#CD012395-bbs2-0048" title="MerliniG , Planté‐BordeneuveV , JudgeDP , SchmidtH , ObiciL , PerliniS , et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non‐Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research2013;6(6):1011‐20. ">Merlini 2013</a>). </p> <p>A prospective non‐RCT of tafamidis was conducted by the French Network for FAP and enrolled 37 participants with Val30Met TTR‐FAP both in early and advanced stages between December 2009 and July 2011. In the 12‐month follow‐up period, 24% of participants deteriorated with respect to disability, measured on the Polyneuropathy Disability Score (<a href="#CD012395-tbl-0005">Table 1</a>), and 31% of participants deteriorated with respect to the severity of neuropathy, measured on the NIS‐LL (<a href="#CD012395-tbl-0005">Table 1</a>). Adverse events caused 7/37 (18.9%) participants to withdraw from the study. A total of 19 adverse events were reported, including febrile urinary tract infections and cases of severe diarrhoea (<a href="./references#CD012395-bbs2-0043" title="LozeronP , ThéaudinM , MinchevaZ , DucotB , LacroixC , AdamsD , French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology2013;20(12):1539‐45. ">Lozeron 2013</a>). </p> <p>A phase 3, open‐label study evaluated the safety, tolerability, and efficacy of tafamidis 20 mg once daily for up to 78 weeks in 10 Japanese people with Val30Met or non‐Val30Met TTR‐FAP (<a href="https://clinicaltrials.gov/show/NCT01435655" target="_blank">NCT01435655</a>). This study did not assess disability due to FAP progression according to our predetermined outcome measures. At week 78, the mean (SD) increase from baseline in the NIS‐LL (which was herein reported with a different range: 0 to 44, with higher scores indicating greater deficits) was 3.3 ± 4.74 points, whereas the mean (SD) increase from baseline in the mBMI was 53.65 ± 81.39 kg/m<sup>2</sup> g/L. After 78 weeks, the mean (SD) increase from baseline in the Norfolk‐QOL total score (range: ‐4 to 136, with lower scores indicating better quality of life; MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>) was 10.8 ± 13.69. During this study, 2/10 (20%) participants died, 10/10 (100%) experienced adverse events, and 7/10 (70%) had severe adverse events. </p> </section> <section id="CD012395-sec-0115"> <h5 class="title">Patisiran</h5> <p>A phase 2, open‐label extension study evaluated long‐term safety, tolerability, and efficacy of patisiran in people with TTR‐FAP (NCT01961921; <a href="./references#CD012395-bbs2-0005" title="AdamsD , CoelhoT , ConceicaoI , Waddington CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24‐month safety and efficacy in subgroup of patients with cardiac involvement. European Journal of Heart Failure2017;19(Suppl S1):19. AdamsD , CoelhoT , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran with or without a TTR stabilizer for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. European Journal of Neurology2017;24(Suppl 1):31‐2. AdamsD , CoelhoT , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational RNA interference (RNAi) therapeutic for the treatment of hereditary attr amyloidosis with polyneuropathy. Value in Health2017;20(5):A211‐2. AdamsD , SuhrO , ConceicaoI , Waddington‐CruzM , SchmidtH , BuadesJ , et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP). Orphanet Journal of Rare Diseases2015;10:1‐2. ">Adams 2015</a>), who completed the pivotal RCT of patisiran (<a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a>). This study was initiated in 2013 and enrolled 27 participants, who received patisiran 0.3 mg/kg intravenously every three weeks for up to two years. At month 24, the median decrease from baseline in the Rasch‐built Overall Disability Scale (which was herein reported with a different range: 0 to 100, with lower scores indicating greater disability) was 1.0 point (full range ‐14.0 to 8.0). At the same time point, the median decrease from baseline in the mNIS+7Alnylam (range: 0 to 304, with higher scores indicating greater deficits; MCID not provided; <a href="#CD012395-tbl-0005">Table 1</a>) was 7.0 points (full range ‐34.63 to 15.38), and the median decrease from baseline in the mBMI was 39.85 kg/m<sup>2</sup> g/L (full range ‐368.8 to 258.9). During this study, 2/27 (7.4%) participants died, 26/27 (96.3%) experienced at least one adverse event, and 7/27 (25.9%) had a severe adverse event. </p> </section> <section id="CD012395-sec-0116"> <h5 class="title">Inotersen</h5> <p>An ongoing, phase 3, open‐label extension study was designed to evaluate long‐term efficacy and safety of inotersen in people with TTR‐FAP who were enrolled and completed the pivotal RCT of inotersen (<a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>), and started in 2014 (NCT02175004; <a href="./references#CD012395-bbs2-0011" title="DasguptaNR , FalkRH , DrachmanBM , MaurerMS , WhelanCJ , BrannaganT , et al. Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy. Journal of the American College of Cardiology2019;73(9 Suppl 1):909. Plante‐BordeneuveV , BrannaganT , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Long‐term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open‐label extension of the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):30. ">Plante‐Bordeneuve 2018</a>). Participants received inotersen 300 mg weekly subcutaneously up to five years. Definitive results have not been released to date. </p> </section> <section id="CD012395-sec-0117"> <h5 class="title">Other evidence</h5> <p>Pre‐clinical studies demonstrated that both the tetracycline antibiotic doxycycline and a combination of doxycycline and the antiapoptotic agent tauroursodeoxycholic acid (TUDCA) inhibited amyloid formation and promoted the disruption of amyloid deposits in murine FAP models (<a href="./references#CD012395-bbs2-0022" title="CardosoI , SaraivaMJ . Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB Journal2006;20(2):234‐9. ">Cardoso 2006</a>; <a href="./references#CD012395-bbs2-0023" title="CardosoI , MartinsD , RibeiroT , MerliniG , SaraivaMJ . Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine2010;8:74. ">Cardoso 2010</a>). Based on these data, in 2012 the European Medicinal Agency granted doxycycline orphan drug designation for TTR‐FAP. A phase 2 open‐label study was designed to evaluate the efficacy, tolerability, safety, and pharmacokinetics of orally administered doxycycline (100 mg, twice daily) and TUDCA (250 mg, 3 times daily) for one year (<a href="./references#CD012395-bbs2-0052" title="ObiciL , CorteseA , LozzaA , LucchettiJ , GobbiM , PalladiniG , et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid2012;19(Suppl 1):34‐6. ">Obici 2012</a>). Results provided evidence that the investigational molecules stabilised the disease for at least one year in the majority of participants, with a favourable toxicity profile (<a href="./references#CD012395-bbs2-0052" title="ObiciL , CorteseA , LozzaA , LucchettiJ , GobbiM , PalladiniG , et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid2012;19(Suppl 1):34‐6. ">Obici 2012</a>). </p> <p>SOM0226/CRX1008 (tolcapone) is a repositioned molecule which is being evaluated for its recently recognised activity in TTR stabilisation and fibril disruption (<a href="./references#CD012395-bbs2-0064" title="Sant'AnnaR , GallegoP , RobinsonLZ , Pereira‐HenriquesA , FerreiraN , PinheiroF , et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications2016;7:10787. ">Sant'Anna 2016</a>). A proof‐of‐concept open‐label, phase 2a clinical trial was conducted in six healthy volunteers and 15 people with TTR‐FAP and asymptomatic carriers (<a href="./references#CD012395-bbs2-0059" title="ReigN , VenturaS , SalvadóM , GámezJ , InsaR . SOM0226, a repositioned compound for the treatment of TTR amyloidosis. Orphanet Journal of Rare Disease2015;10(Suppl 1):P9. ">Reig 2015</a>). This study demonstrated that a single oral dose of 200 mg or three doses of 100 mg SOM0226 stabilised plasmatic TTR in all participants studied, and did not report any adverse events related to the investigational compound, thus supporting further clinical development of SOM0226 for the treatment of TTR‐FAP. </p> <p>Epigallocatechin‐3‐gallate (EGCG), the most abundant polyphenol in green tea, has been observed to reduce extracellular TTR deposition in the peripheral nervous system of a FAP transgenic mouse model (<a href="./references#CD012395-bbs2-0034" title='FerreiraN , SaraivaMJ , AlmeidaMR . Epigallocatechin‐3‐gallate as a potential therapeutic drug for TTR‐related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One2012;7(1):e29933. '>Ferreira 2012</a>). Subsequently, a single‐centre observational study reported no progression in left ventricular wall thickness and mass on echocardiography in a small cohort of people with hereditary and non‐hereditary forms of cardiac TTR amyloidosis, including eight people with hereditary TTR cardiomyopathy, after daily consumption of EGCG in the form of green tea or green tea extract for 12 months (<a href="./references#CD012395-bbs2-0041" title="KristenAV , LehrkeS , BussS , MerelesD , SteenH , EhlermannP , et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clinical Research in Cardiology2012;101(10):805‐13. ">Kristen 2012</a>). However, no studies have investigated the potential effect of EGCG on FAP progression. </p> </section> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012395-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA chart for searched to included studies for FAPs" data-id="CD012395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA chart for searched to included studies for FAPs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012395-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 1 Severity of peripheral neuropathy (expressed as the change from baseline in NIS‐LL)." data-id="CD012395-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 1 Severity of peripheral neuropathy (expressed as the change from baseline in NIS‐LL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 2 Change in mBMI." data-id="CD012395-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 2 Change in mBMI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 3 Quality of life (expressed as the change from baseline in Norfolk QOL‐DN total score)." data-id="CD012395-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 3 Quality of life (expressed as the change from baseline in Norfolk QOL‐DN total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 4 Number of participants who died during the trial (published paper ‐ see text)." data-id="CD012395-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 4 Number of participants who died during the trial (published paper ‐ see text). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 5 Number of participants experiencing at least one adverse event." data-id="CD012395-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 5 Number of participants experiencing at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing mild adverse events." data-id="CD012395-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing mild adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 7 Number of dropouts due to adverse events." data-id="CD012395-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 7 Number of dropouts due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing at least one severe adverse event." data-id="CD012395-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Tamafidis versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing at least one severe adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 1 Disability due to FAP progression (expressed as the change from baseline in KS)." data-id="CD012395-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 1 Disability due to FAP progression (expressed as the change from baseline in KS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 2 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS+7)." data-id="CD012395-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 2 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS+7). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 3 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS)." data-id="CD012395-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 3 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 4 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS‐LL)." data-id="CD012395-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 4 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS‐LL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 5 Change in mBMI." data-id="CD012395-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 5 Change in mBMI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 6 Quality of life (expressed as the change from baseline in SF‐36 physical score)." data-id="CD012395-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 6 Quality of life (expressed as the change from baseline in SF‐36 physical score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 7 Quality of life (change in SF‐36 mental score)." data-id="CD012395-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 7 Quality of life (change in SF‐36 mental score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 8 Number of participants who died during the trial." data-id="CD012395-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 8 Number of participants who died during the trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 9 Number of participants experiencing mild adverse events." data-id="CD012395-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 9 Number of participants experiencing mild adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 10 Number of dropouts due to adverse events." data-id="CD012395-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 10 Number of dropouts due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 11 Number of participants experiencing at least one severe adverse event." data-id="CD012395-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Diflunisal versus placebo in TTR‐FAP, Outcome 11 Number of participants experiencing at least one severe adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 1 Disability due to FAP progression (expressed as the change from baseline in the R‐ODS), at 18 months." data-id="CD012395-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 1 Disability due to FAP progression (expressed as the change from baseline in the R‐ODS), at 18 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 2 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Alnylam), at 18 months." data-id="CD012395-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 2 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Alnylam), at 18 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 3 Change in mBMI, at 18 months." data-id="CD012395-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 3 Change in mBMI, at 18 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 4 Quality of life (change in Norfolk QOL‐DN total score), at 18 months." data-id="CD012395-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 4 Quality of life (change in Norfolk QOL‐DN total score), at 18 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 5 Number of participants who died during the trial." data-id="CD012395-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 5 Number of participants who died during the trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing at least one adverse event." data-id="CD012395-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 7 Number of participant dropouts due to adverse events (data from published paper ‐ see text)." data-id="CD012395-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 7 Number of participant dropouts due to adverse events (data from published paper ‐ see text). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing at least one severe adverse event." data-id="CD012395-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing at least one severe adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 1 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Ionis), at 66 weeks." data-id="CD012395-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 1 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Ionis), at 66 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 2 Change in mBMI from baseline to 65 weeks." data-id="CD012395-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 2 Change in mBMI from baseline to 65 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 3 Quality of life (change in Norfolk QOL‐DN total score), at 66 weeks." data-id="CD012395-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 3 Quality of life (change in Norfolk QOL‐DN total score), at 66 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 4 Quality of life (change in SF‐36 physical component), at 66 weeks." data-id="CD012395-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 4 Quality of life (change in SF‐36 physical component), at 66 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 5 Number of participants who died during the trial." data-id="CD012395-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 5 Number of participants who died during the trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing at least one adverse event." data-id="CD012395-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 6 Number of participants experiencing at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 7 Number of participants experiencing at least one adverse event related to the study medication." data-id="CD012395-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 7 Number of participants experiencing at least one adverse event related to the study medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing mild adverse events." data-id="CD012395-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 8 Number of participants experiencing mild adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 9 Number of dropouts due to adverse events." data-id="CD012395-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 9 Number of dropouts due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 10 Number of participants experiencing at least one severe adverse event." data-id="CD012395-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 10 Number of participants experiencing at least one severe adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012395-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/urn:x-wiley:14651858:media:CD012395:CD012395-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_t/tCD012395-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 11 Number of participants experiencing at least one severe adverse event related to the study medication." data-id="CD012395-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Inotersen versus placebo in TTR‐FAP, Outcome 11 Number of participants experiencing at least one severe adverse event related to the study medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/media/CDSR/CD012395/image_n/nCD012395-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012395-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with early‐stage TTR‐FAP<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> tafamidis<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tafamidis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability due to FAP progression was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b> (expressed as the change in NIS‐LL) </p> <p>Scale from: 0 (normal) to 88 (total impairment)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline NIS‐LL score in the placebo group was <b>11.44</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>5.40</b> points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NIS‐LL score in the tafamidis group was <b>3.21</b> points lower (better) than in the placebo group<br/> (<b>5.63</b> points lower to <b>0.79</b> points lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (1 RCT)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID is 2 NIS‐LL points according to a Peripheral Nerve Society consensus group (<a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a>). </p> <p>Tafamidis probably slightly reduces the number of people with progression of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in 35‐Item Norfolk QOL‐DN total score)<br/> Scale from: ‐2 (best possible quality of life) to 138 (worst possible quality of life)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>30.80</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>6.90</b> points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the tafamidis group was <b>4.50</b> points lower (better) than in the placebo group<br/> (<b>11.27</b> points lower to <b>2.27</b> points higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (1 RCT)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID was not provided nor reported in the literature.</p> <p>Quality of life may decline slightly less with tafamidis than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b><br/> (0.11 to 3.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of participants who died during the trial compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b><br/> (1 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.29</b><br/> (0.30 to 5.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of dropouts due to adverse events compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/> (1 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/> (0.37 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/> (1 RCT)<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether tafamidis had an effect on the number of participants experiencing at least one severe adverse event compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b><br/> (3 to 29) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>NIS‐LL:</b> Neuropathy Impairment Score of the lower limbs; <b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Intention‐to‐treat population.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by one level for serious imprecision (CI encompassed a clinically important effect and little or no effect).<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision (CI is wide and includes the possibility of both harms and benefits) and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>Randomised population (safety population).<br/> <sup>f</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by two levels for very serious imprecision (small event numbers; and CI includes the possibility of both harms and benefits) and by one level for serious indirectness (events collected by a non‐systematic assessment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tafamidis compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012395-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> diflunisal<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with diflunisal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> (expressed as the change in Kumamoto Score) </p> <p>Scale from: 0 (normal) to 102 (worst disease severity).<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Kumamoto Score in the placebo group was <b>16.7</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>8.0</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Kumamoto Score in the diflunisal group was <b>4.90</b> points lower (better) than in the placebo group (<b>7.89</b> points lower to <b>1.91</b> points lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Diflunisal probably slightly decreases disability due to FAP progression compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b> (expressed as the change in NIS+7) </p> <p>Scale from: 0 (normal) to 270 (total impairment)<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline NIS+7 score in the placebo group was <b>59.0</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>26.3</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NIS+7 score in the diflunisal group was <b>18.10</b> points lower (better) than in the placebo group (<b>26.03</b> points lower to <b>10.17</b> points lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID detectable by neuromuscular experts is 2 NIS+7 points according to the international Peripheral Nerve Society (<a href="./references#CD012395-bbs2-0055" title="Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Annals of Neurology1995;38(3):478–82. [DOI: 10.1002/ana.410380323; PUBMED: 7668839] ">PNS 1995</a>). </p> <p>Diflunisal probably slightly reduces the worsening of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in SF‐36 physical component score) </p> <p>Scale from: 0 (worst possible quality of life) to 100 (best possible quality of life)<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline SF‐36 QOL score (physical component) in the placebo group was <b>34.8</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>4.9</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SF‐36 QOL score (physical component) in the diflunisal group was <b>6.10</b> points higher (better) than in the placebo group (<b>2.56</b> points higher to <b>9.64</b> points higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID proposed in the <a href="./references#CD012395-bbs2-0065" title="User's manual for the SF‐36v2 survey. 3rd ed. Lincoln (RD), Quality Metric Incorporated2011. ">SF‐36v2 2011</a> is 2 points on the physical component summary. </p> <p>QOL (physical status) may decline slightly less with diflunisal than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in SF‐36 mental component score) </p> <p>Scale from: 0 (worst possible quality of life) to 100 (best possible quality of life).<br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline SF‐36 QOL score (mental component) in the placebo group was <b>46.5</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>0.9</b> points. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SF‐36 QOL score (mental component) in the diflunisal group was <b>4.40</b> points higher (better) than in the placebo group (<b>0.19</b> points lower to <b>8.99</b> points higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID proposed in the <a href="./references#CD012395-bbs2-0065" title="User's manual for the SF‐36v2 survey. 3rd ed. Lincoln (RD), Quality Metric Incorporated2011. ">SF‐36v2 2011</a> is 3 points on the mental component summary. </p> <p>Quality of life (mental status) may decline slightly less with diflunisal than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b><br/> (0.15 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is evidence that there may be fewer deaths among people treated with diflunisal</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/> (2 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.06</b><br/> (0.39 to 10.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diflunisal may increase the number of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b><br/> (3 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 24 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b><br/> (0.18 to 3.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diflunisal may have no clear effect on the number of participants experiencing at least one severe adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (1 to 20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>NIS+7:</b> Neuropathy Impairment Score plus 7 nerves test; <b>QOL</b> : quality of life; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SF‐36:</b> 36‐Item Short‐Form Health Survey; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by one level for serious imprecision.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision and by one level for serious indirectness (data regarding QOL provided for SF‐36 physical and mental components separately).<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison), by one level for serious imprecision (CI includes the possibility of both harms and benefits) and by one level for serious indirectness (data regarding QOL provided for SF‐36 physical and mental components separately and mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by one level for risk of bias (high risk of attrition bias in the single RCT included in this comparison) and by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diflunisal compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012395-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> patisiran<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with patisiran</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> (expressed as the change in R‐ODS) </p> <p>Scale from: 0 (worst disability) to 48 (normal)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline R‐ODS score in the placebo group was <b>29.8</b> points. </p> <p>The mean change from baseline in the placebo group was a decrease (worsening) of <b>8.9</b> points.<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in R‐ODS score in the patisiran group was <b>8.90</b> points higher (better) than in the placebo group (<b>7.00</b> points higher to <b>10.80</b> points higher).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Patisiran probably decreases disability due to FAP progression compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b><br/> (expressed as the change in mNIS+7ALN) </p> <p>Scale from: 0 (normal) to 304 (total impairment)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline mNIS+7ALN score in the placebo group was <b>74.6</b> points. </p> <p>The mean change from baseline in the placebo group was an increase (worsening) of <b>27.96</b> points.<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mNIS+7ALN score in the patisiran group was <b>33.99</b> points lower (better) than in the placebo group (<b>39.86</b> points lower to <b>28.13</b> points lower).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not available for this modified NIS+7 scores.</p> <p>Patisiran probably slightly reduces the worsening of peripheral neuropathy compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> (expressed as the change in 35‐Item Norfolk QOL‐DN total score) </p> <p>Scale from: ‐4 (best possible quality of life) to 136 (worst possible quality of life)<br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>55.5</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>14.4</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the patisiran group was <b>21.10</b> points lower (better) than in the placebo group (<b>27.20</b> points lower to <b>15.00</b> points lower).<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID not provided nor reported in the literature.</p> <p>Quality of life may decline slightly less with patisiran than placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b><br/> (0.21 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be no clear difference between the patisiran group and the placebo group in the number of participants who died during the trial. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (2 to 14) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.33</b><br/> (0.13 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between the patisiran group and the placebo group in the number of dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b><br/> (2 to 12) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 18 months<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.91</b><br/> (0.64 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between the patisiran group and the placebo group in the number of participants with at least one severe adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b><br/> (26 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval;<b>FAP:</b> familial amyloid polyneuropathy;<b>MCID:</b> minimum clinically important difference; <b>mNIS+7ALN:</b> modified Neuropathy Impairment Score plus 7 nerves test (Alnylam);<b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial;<b>ROD‐S:</b> Rasch‐built Overall Disability Scale; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Means change from baseline and mean differences between groups refer to least‐squares means and least‐squares mean differences, respectively.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for serious imprecision.<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for serious imprecision and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits).<br/> <sup>f</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Patisiran compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012395-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with TTR‐FAP<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> inotersen<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inotersen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability due to FAP progression</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability due to FAP progression was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity of peripheral neuropathy</b><br/> (expressed as the change in mNIS+7Ionis) </p> <p>Scale from: ‐22.3 (normal) to 346.3 (total impairment)</p> <p>Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline mNIS+7Ionis score in the placebo group was <b>74.8</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>23.89</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mNIS+7Ionis score in the inotersen group was <b>19.73</b> points lower (better) than in the placebo group (<b>26.50</b> lower to <b>12.96</b> lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MCID detectable is 2 points.</p> <p>Inostersen probably reduces the worsening of peripheral neuropathy compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (expressed as the change in 35‐Item Norfolk QOL‐DN total score) </p> <p>Scale from: ‐4 (best possible quality of life) to 136 (worst possible quality of life)</p> <p>Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean baseline Norfolk QOL score in the placebo group was <b>48.7</b> points. The mean change from baseline in the placebo group was an increase (worsening) of <b>10.77</b> points<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Norfolk QOL score in the inotersen group was <b>10.85</b> points lower (better) than in the placebo group (<b>17.25</b> lower to <b>4.45</b> lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MICD not provided nor reported in the literature.</p> <p>Inotersen may have little effect on the change in QOL.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants who died during the trial</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.94</b><br/> (0.33 to 105.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of participants who died during the trial may be greater in the inotersen group than in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0/60 deaths</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5/112 deaths</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of dropouts due to adverse events</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 8.57</b><br/> (1.16 to 63.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of dropouts due to adverse events may be greater in the inotersen group than the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b><br/> (2 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing at least one severe adverse event</b><br/> Follow‐up: 66 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.48</b><br/> (0.85 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>172<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The number of participants experiencing at least one severe adverse event may be greater in the inotersen group than in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b><br/> (18 to 56) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FAP:</b> familial amyloid polyneuropathy; <b>MCID:</b> minimum clinically important difference; <b>mNIS+7Ionis</b> : modified Neuropathy Impairment Score plus 7 nerves test (Ionis version); <b>QOL‐DN:</b> Quality of Life‐Diabetic Neuropathy Questionnaire; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio; <b>TTR:</b> transthyretin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>End of the study.<br/> <sup>b</sup>Mean change from baseline and mean differences between groups refer to least‐squares means and least‐squares mean differences, respectively.<br/> <sup>c</sup>We downgraded the certainty of evidence by one level for serious imprecision.<br/> <sup>d</sup>We downgraded the certainty of evidence by one level for serious imprecision and by one level for serious indirectness (mechanisms by which this intervention would affect QOL are not direct).<br/> <sup>e</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and CI includes the possibility of both harms and benefits).<br/> <sup>f</sup>We downgraded the certainty of evidence by two levels for very serious imprecision (small event numbers and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Inotersen compared to placebo for people with transthyretin‐familial amyloid polyneuropathy (TTR‐FAP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012395-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Scores included as outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Instrument name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Direction of response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data analysed as</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Stage of disease based on disability or disability</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical staging of TTR‐FAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAP stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0027" title="CoutinhoP , Martins da SilvaA , Lopes LimaJ , Resende BarbosaA . Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: GlennerG , CostaP , deFreitasA editor(s). Amyloid and Amyloidosis. Amsterdam: Execerpta Medica, 1980:88‐98. ">Coutinho 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyneuropathy Disability Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater walking disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0068" title="SteenL , EkB . Familial amyloidosis with polyneuropathy. A long‐term follow‐up of 21 patients with special reference to gastrointestinal symptoms. Acta Medica Scandinavica1983;214:387–97. ">Steen 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Norris Test Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 to 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0042" title="LacomblezL , BoucheP , BensimonG , MeiningerV . A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology1989;39(12):1635–7. ">Lacomblez 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Portuguese classification system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0063" title="Sales‐LuísML , GalvãoM , SousaG , AlvesMM , SerrãoR . Plasma exchanges on: the treatment of familial amyloidotic polyneuropathy, Portuguese type. Familial amyloidotic polyneuropathy and other transthyretin related disorders. Arquivos de Medicina1990;3:361‐9. ">Sales‐Luís 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kumamoto Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0071" title="TashimaK , AndoY , TerazakiH , YoshimatsuS , SuhrOB , ObayashiK , et al. Outcome of liver transplantation for transthyretin amyloidosis: follow‐up of Japanese familial amyloidotic polyneuropathy patients. Journal of the Neurological Sciences1999;171(1):19‐23. ">Tashima 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yamamoto Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0076" title="YamamotoS , WilczekH , NowakG , LarssonM , OksanenA , IwataT , et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single‐center experience over 16 years. American Journal of Transplantation2007;7(11):2597–604. ">Yamamoto 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rasch‐built Overall Disability Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R‐ODS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0073" title="vanNesSI , VanhoutteEK , vanDoornPA , HermansM , BakkersM , KuitwaardK , et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology2011;76(4):337‐45. ">van Nes 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Impairment due to nerve function</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0031" title="DyckPJ , LitchyWJ , LehmanKA , HokansonJL , LowPA , O'BrienPC . Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology1995;45(6):1115‐21. ">Dyck 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score in the lower limbs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS‐LL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0021" title="BrilV . NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology1999;41(Suppl 1):8‐13. ">Bril 1999</a>; <a href="./references#CD012395-bbs2-0032" title="DyckPJ , DaviesJL , LitchyWJ , O’BrienPC . Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology1997;49(1):229‐39. ">Dyck 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score in the upper limbs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS‐UL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0043" title="LozeronP , ThéaudinM , MinchevaZ , DucotB , LacroixC , AdamsD , French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology2013;20(12):1539‐45. ">Lozeron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Impairment Score plus 7 nerve tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS+7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0003" title="BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2010;17(Suppl 1):78. [EMBASE: 70725032] BerkJL , DyckPJ , ObiciL , ZeldenrustSR , SekijimaY , YamashitaT , et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid2011;18(Suppl 1):196‐7. [PUBMED: 21838485] BerkJL , SuhrOB , ObiciL , SekijimaY , ZeldenrustSR , YamashitaT , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013;310(24):2658–67. [PUBMED: 24368466] BerkJL , SuhrOB , SekijimaY , YamashitaT , HeneghanM , ZeldenrustSR , et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid2012;19(Suppl 1):37‐8. [PUBMED: 22551208] ">Berk 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Neuropathy Impairment Score plus 7 nerve tests (Alnylam version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mNIS+7Alnylam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0069" title="SuanprasertN , BerkJL , BensonMD , DyckPJ , KleinCJ , GollobJA , et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences2014;344(1‐2):121‐8. ">Suanprasert 2014</a>; <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Neuropathy Impairment Score plus 7 nerve tests (Ionis version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mNIS+7Ionis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐22.3 to 346.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0069" title="SuanprasertN , BerkJL , BensonMD , DyckPJ , KleinCJ , GollobJA , et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences2014;344(1‐2):121‐8. ">Suanprasert 2014</a>; <a href="./references#CD012395-bbs2-0033" title="DyckPJ , KincaidJC , DyckPJ , ChaudhryV , GoyalNA , AlvesC , et al. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle &amp; Nerve2017;56(5):901‐11. ">Dyck 2017</a>; <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Charcot‐Marie Tooth Neuropathy Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMTNS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0066" title="ShyME , BlakeJ , KrajewskiK , FuerstDR , LauraM , HahnAF , et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology2005;64(7):1209‐14. ">Shy 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Charcot‐Marie Tooth Neuropathy Score 2nd version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMTNS2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0050" title="MurphySM , HerrmannDN , McDermottMP , SchererSS , ShyME , ReillyMM , et al. Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease. Journal of the Peripheral Nervous System2011;16(3):191‐8. ">Murphy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy Disability Score revised version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rNDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater deficits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0016" title="AbbottCA , CarringtonAL , AsheH , BathS , EveryLC , GriffithsJ , et al. The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort. Diabetic Medicine2002;19(5):377‐84. ">Abbott 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compound Autonomic Dysfunction Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate greater autonomic impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0029" title="DenierC , DucotB , HussonH , LozeronP , AdamsD , MeyerL , et al. A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy. Journal of Neurology2007;254(12):1684–8. ">Denier 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Wasting and autonomic gastrointestinal function</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified body mass index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mBMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Product of the BMI (kg/m<sup>2</sup>) </p> <p>and serum albumin concentration (g/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate greater wasting (worse nutritional status)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0070" title="SuhrO , DanielssonA , HolmgrenG , SteenL . Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. Journal of Internal Medicine1994;235(5):479‐85. ">Suhr 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Quality of life</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short Form 36 Health Survey Questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0075" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473–83. ">Ware 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norfolk Quality of Life–Diabetic Neuropathy Questionnaire<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norfolk QOL‐DN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2 to 138</p> <p>‐4 to 136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0074" title="VinikEJ , HayesRP , OglesbyA , BastyrE , BarlowP , Ford‐MolvikSL , et al. The development and validation of the Norfolk QOL‐DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology &amp; Therapeutics2005;7(3):497‐508. ">Vinik 2005</a> </p> <p><a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> </p> <p><a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EuroQoL Quality of Life Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQ‐5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0056" title="RabinR , deCharroF . EQ‐5D: a measure of health status from the EuroQolGroup. Annals of Medicine2001;33(5):337‐43. ">Rabin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Karnofsky Performance Status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Karnofsky</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower scores indicate</p> <p>worse status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0077" title="YatesJW , ChalmerB , McKegneyFP . Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer1980;45:2220–4. ">Yates 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Depression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beck Depression Inventory 2nd version</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDI‐II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher total scores indicate more severe depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0020" title="BeckAT , SteerRA , GarbinMG . Psychometric properties of the Beck Depression Inventory: twenty‐five years of evaluation. Clinical Psychology Review1988;8(1):77‐100. ">Beck 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamilton Depression Rating Scale for Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HAM‐D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher total scores indicate more severe depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012395-bbs2-0035" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery &amp; Psychiatry1960;23:56‐62. ">Hamilton 1960</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Slightly different score ranges are reported in different RCTs (range (‐2 to 138) in <a href="./references#CD012395-bbs2-0004" title="CoelhoT . Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology2012;19(Suppl 1):8. [EMBASE: 70938581] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid2010;17(Suppl 1):75‐6. [EMBASE: 70725028] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , LozeronP , et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology2012;123(6):e56. [EMBASE: 70824746] CoelhoT , MaiaL , Martins Da SilvaA , Waddingtion‐CruzM , Plante‐BordeneuveV , SuhrOB , et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System2009;14(Suppl 2):35‐6. [EMBASE: 70008473] CoelhoT , MaiaLF , Martins da SilvaA , Waddington‐CruzM , Planté‐BordeneuveV , LozeronP , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology2012;79(8):785‐92. [PUBMED: 22843282] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid2017;24(1):30‐6. [PUBMED: 28393570] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post‐hoc analyses of a pivotal trial. European Journal of Neurology2015;22(Suppl 1):413. [EMBASE: 71933792] KeohaneD , SchwartzJ , GundapaneniB , StewartM , AmassL . Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post‐hoc analyses of a pivotal trial. Orphanet Journal of Rare Diseases2015;10(Suppl 1):P11. [EMBASE: 613537301] SuhrOB , ConceicaoI , KarayalO , EriczonBG . Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. European Journal of Neurology2012;19(Suppl 1):775. [EMBASE: 70939980] SuhrOB , ConceicaoIM , KarayalON , MandelFS , HuertasPE , EriczonB . Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurology and Therapy2014;3(2):101‐12. [PUBMED: 26000226] ">Coelho 2012</a> and range (‐4 to 136) in <a href="./references#CD012395-bbs2-0001" title="AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825] AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619389882] AdamsD , Gonzalez‐DuarteA , O'RiordanWD , YangCC , UedaM , KristenAV , et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):11‐21. [PUBMED: 29972753 ] AdamsD , PriteshJG . Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique2019;175(Suppl 1):S129. AdamsD , SuhrOB , DyckPJ , LitchyWJ , LeahyRG , ChenJ , et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurology2017;17(1):181. [PUBMED: 28893208] Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial. Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN2019;92(15 Suppl 1):2019. Ajroud‐DrissS , AdamsD , CoelhoT , PolydefkisM , Gonzalez‐DuarteA , QuanD , et al. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Journal of the Peripheral Nervous System2018;23(4):272‐3. BerkJL , ConceicaoI , Waddington‐CruzM , PolydefkisM , CoelhoT , PartisanoAM , et al. Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial. Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA2018;84(Suppl 22):S180. CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Impact of prior TTR stabilizer use in patients with hereditary transthyretin‐mediated amyloidosis in the APOLLO phase‐3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):17‐8. [EMBASE: 623298109] CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , YamashitaT , et al. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. European Journal of Neurology2018;25(Suppl 2):353‐4. [EMBASE: 623298597 ] CoelhoT , AdamsD , González‐DuarteA , O'RiordanW , YangCC , PolydefkisM , et al. Transthyretin reduction with patisiran in the APOLLO phase 3 study. Journal of Neuromuscular Diseases2018;5(Suppl 1):S261‐2. Gonzalez‐DuarteA , AdamsD , MauermannM , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated (hATTR) amyloidosis patients. Clinical Autonomic Research2018;28(5):466. Gonzalez‐DuarteA , AdamsD , O'RiordanW , YangCC , YamashitaT , KristenA , et al. Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO. Journal of the Peripheral Nervous System2018;23(4):400. JudgeDP , Gonzalez‐DuarteA , DispenzieriA , LinH , MerkelM , WangY , et al. Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin‐mediated amyloidosis. Journal of Cardiac Failure2019;25(8 Suppl):S78. MauermannM , AdamsD , Gonzalez‐DuarteA , CoelhoT , YangCC , PolydefkisM , et al. Impact of patisiran on autonomic neuropathy in hereditary transthyretin‐mediated amyloidosis patients. Journal of Neuromuscular Diseases2018;5(Suppl 1):S220‐1. MerliniG , SolomonS , AdamsD , CoelhoT , DamyT , MauerM , et al. Impact of patisiran on Norfolk QOL‐DN in patients with hereditary transthyretin‐mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study. European Journal of Heart Failure2018;20(Suppl 1):383. [EMBASE: 622650519 ] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL‐DN) in patients with hereditary transthyretin‐mediated amyloidosis: results from the phase‐3 APOLLO study. European Journal of Neurology2018;25(Suppl 2):459. [EMBASE: 623297736] ObiciL , CoelhoT , AdamsD , Gonzalez‐DuarteA , O'RiordanW , YangCC , et al. Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin‐mediated amyloidosis. European Journal of Neurology2018;25(Suppl 2):17. [EMBASE: 623298051] PartisanoA , SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study. Orphanet Journal of Rare Diseases2017;12(Suppl 1):165. [EMBASE: 619390286] PolydefkisM , AdamsD , CoelhoT , KristenA , Gonzalez‐DuarteA , BerkJ , et al. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Journal of the Peripheral Nervous System2018;23(4):352. QuanD , AdamsD , González‐DuarteA , PolydefisM , KristenA , TournevI , et al. Evaluating the impact of patisiran on disability using the Rasch‐built overall disability scale (R‐ODS) in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis in the APOLLO study. Muscle &amp; Nerve2018;58(Suppl 2):S51. SchmidtH , O'RiordanW , YamashitaT , BerkJL , TournevI , MezeiM , et al. Reasons for discontinuation of TTR stabilizers and/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study. Annals of Neurology2017;82(Suppl 21):S100‐1. [EMBASE: 619084531 ] SlamaMS , SolomonS , AdamsD , CoelhoT , DamyT , MerliniG , et al. Analysis of NT‐proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin‐mediated (hATTR) amyloidosis. European Journal of Heart Failure2018;20(Suppl 1):576. [EMBASE: 622651967] SolomonSD , AdamsD , KristenA , GroganM , González‐DuarteA , MaurerMS , et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin‐mediated amyloidosis. Analysis of the APOLLO study. Circulation2019;139(4):431‐43. ZhangX , GoelV , AttarwalaH , SweetserMT , ClausenVA , RobbieGJ . Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. Journal of Clinical Pharmacology2019;19:19. ZhangX , SweetserMT , RobbieGJ . Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy. Clinical Pharmacology and Therapeutics2019;105(Suppl 1):S31. [Abstract: E‐009] ">Adams 2018</a> and <a href="./references#CD012395-bbs2-0002" title="Anonymous . Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart &amp; Lung2019;48(5):469‐71. BensonM , KincaidJ , AckermannE , MoniaB . A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ] BensonM , Waddington‐CruzM , WangA , PolydefkisM , Plante‐BordeneuveV , BerkJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases2017;12(Suppl 1):165‐6. [EMBASE: 619389834] BensonMD , Waddington‐CruzM , BerkJL , PolydefkisM , DyckPJ , WangAK , et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine2018;379(1):22‐31. [PUBMED: 29972757] CoelhoT , WangA , Waddington‐CruzM , PolydefkisM , DyckP , ScheinbergM , et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):376. [EMBASE: 623298254] ConceicaoI , BerkJ , WangA , CoelhoT , Waddington‐CruzM , PolydefkisM , et al. Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO‐TTR demonstrate significant disease burden. European Journal of Neurology2018;25(Suppl 2):375. [EMBASE: 623298181] DyckPJ , CoelhoT , CruzMW , BrannaganT , KhellaS , KaramC , et al. Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. Neurology2019;92(15 Suppl):P3.9‐060. DyckPJ , CoelhoT , Waddington CruzM , BrannaganT , KhellaS , KaramC , et al. Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):715. DyckPJ , KincaidJC , WiesmanJF , PolydefkisM , LitchyWJ , MauermannML , et al. Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy. European Journal of Neurology2019;26(Suppl 1):714. GertzM , WangA , CruzMW , PolydefisM , DyckP , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Muscle &amp; Nerve2018;58(Suppl 2):S55. GertzM , WangAK , CoelhoT , CruzMW , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1). [Abstract: N2.001] GertzM , WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO‐TTR). Neurology2018;90(15 Suppl 1):N2.001. [EMBASE: 622308128] MaurerMS , HeitnerS , DrachmanB , WhelanC , GuthrieS , TaiL , et al. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO‐TTR. Journal of the American College of Cardiology2018;71(11 Suppl 1):1217M‐03. [EMBASE: 621784581] PolydefkisM , CruzMW , DyckP , ScheinbergM , BerkJ , BarrosoF , et al. Inotersen improves Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO‐TTR. Muscle &amp; Nerve2018;58(Suppl 2):S54. VitaG , PolydefkisM , CoelhoT , Waddington‐CruzM , DyckP , ScheinbergM , et al. Inotersen improved Norfolk quality of life‐diabetic neuropathy (Norfolk QOL‐DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase‐3 study NEURO‐TTR. European Journal of Neurology2018;25(Suppl 2):568‐9. [EMBASE: 623298443] Waddington‐CruzM , AckermannEJ , PolydefkisM , HeitnerSB , DyckPJ , BarrosoFA , et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO‐TTR trial. Amyloid2018;25(3):180‐8. WangAK , CoelhoT , Waddington‐CruzM , PolydefkisMJ , DyckPJ , ScheinbergM , et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro‐TTR). Annals of Neurology2017;82(Suppl 21):S109. [EMBASE: 619084794] YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4812. YarlasA , MerliniG , WhiteMK , KesslerAS , LovleyA , GuthrieSD , et al. Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double‐blind placebo‐controlled trial. Blood2018;132(Suppl 1):4803. ">Benson 2018</a>), although the direction of the scores is the same. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Scores included as outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/full#CD012395-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012395-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tamafidis versus placebo in TTR‐FAP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severity of peripheral neuropathy (expressed as the change from baseline in NIS‐LL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.83 [‐5.99, ‐1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.21 [‐5.63, ‐0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in mBMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>50.2 [24.46, 75.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>70.6 [41.96, 99.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (expressed as the change from baseline in Norfolk QOL‐DN total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.50 [‐9.48, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐11.27, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants who died during the trial (published paper ‐ see text) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.11, 3.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants experiencing at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants experiencing mild adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.30, 5.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants experiencing at least one severe adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.37, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tamafidis versus placebo in TTR‐FAP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012395-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Diflunisal versus placebo in TTR‐FAP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disability due to FAP progression (expressed as the change from baseline in KS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐4.91, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.9 [‐7.89, ‐1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS+7) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.3 [‐11.38, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.1 [‐26.03, ‐10.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐10.17, ‐1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.80 [‐23.82, ‐9.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Severity of peripheral neuropathy (expressed as the change from baseline in the NIS‐LL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.8 [‐5.72, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.3 [‐12.47, ‐4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in mBMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.8 [‐28.27, 67.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.2 [‐18.42, 86.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life (expressed as the change from baseline in SF‐36 physical score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐0.04, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [2.56, 9.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Quality of life (change in SF‐36 mental score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.7 [‐1.98, 5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.4 [‐0.19, 8.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants who died during the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.15, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number of participants experiencing mild adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.75, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.39, 10.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number of participants experiencing at least one severe adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Diflunisal versus placebo in TTR‐FAP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012395-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Patisiran versus placebo in TTR‐FAP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disability due to FAP progression (expressed as the change from baseline in the R‐ODS), at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.9 [7.00, 10.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Alnylam), at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.99 [‐39.86, ‐28.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in mBMI, at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>115.7 [82.40, 149.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life (change in Norfolk QOL‐DN total score), at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.1 [‐27.20, ‐15.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants who died during the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants experiencing at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participant dropouts due to adverse events (data from published paper ‐ see text) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.13, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants experiencing at least one severe adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Patisiran versus placebo in TTR‐FAP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012395-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Inotersen versus placebo in TTR‐FAP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Ionis), at 66 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.73 [‐26.50, ‐12.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in mBMI from baseline to 65 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.89 [‐17.29, 41.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (change in Norfolk QOL‐DN total score), at 66 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.85 [‐17.25, ‐4.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life (change in SF‐36 physical component), at 66 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.6 [‐6.13, ‐1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants who died during the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.94 [0.33, 105.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants experiencing at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants experiencing at least one adverse event related to the study medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.45, 2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants experiencing mild adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number of dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.57 [1.16, 63.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of participants experiencing at least one severe adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.85, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number of participants experiencing at least one severe adverse event related to the study medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [0.55, 33.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Inotersen versus placebo in TTR‐FAP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012395.pub2/references#CD012395-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012395.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012395-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012395-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012395-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012395-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012395-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012395-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012395-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012395-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012395\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012395\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012395\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012395\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012395.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012395.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012395.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012395.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012395.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725314065"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012395.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725314069"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012395.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e78300fa4936e',t:'MTc0MDcyNTMxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 